Document:

Investor Rights Agreement

 Exhibit 10.1 
 EXECUTION COPY 
 INVESTOR RIGHTS AGREEMENT 

dated as of 
 FEBRUARY 1, 2011 
 by and between 

IGATE CORPORATION 
 and 
 VISCARIA LIMITED 

 Table of Contents 

 

							
	 	  	 	  	Page	 
	 Article I Certain Definitions
	  	 	1	  
		
	 Article II Registration Rights
	  	 	6	  
	 Section 2.1
	  	 Mandatory Registration
	  	 	6	  
	 Section 2.2
	  	 Allowed Delay
	  	 	7	  
	 Section 2.3
	  	 Expenses
	  	 	8	  
	 Section 2.4
	  	 Company Obligations
	  	 	8	  
	 Section 2.5
	  	 Due Diligence Review; Information
	  	 	10	  
	 Section 2.6
	  	 Obligations of the Investors
	  	 	11	  
	 Section 2.7
	  	 Indemnification
	  	 	12	  
	 Section 2.8
	  	 Applicability
	  	 	14	  
		
	 Article III Other Rights
	  	 	14	  
	 Section 3.1
	  	 Right of First Offer
	  	 	14	  
	 Section 3.2
	  	 Due Diligence in Connection with Subsequent Financings
	  	 	15	  
	 Section 3.3
	  	 Preemptive Rights
	  	 	15	  
	 Section 3.4
	  	 Additional Rights
	  	 	16	  
	 Section 3.5
	  	 Voting
	  	 	16	  
	 Section 3.6
	  	 Transfers
	  	 	17	  
	 Section 3.7
	  	 Standstill
	  	 	17	  
		
	 Article IV Nomination of Investor Directors
	  	 	17	  
	 Section 4.1
	  	 Investor Directors
	  	 	17	  
	 Section 4.2
	  	 Continuing Designation of Investor Directors
	  	 	18	  
	 Section 4.3
	  	 Event of Noncompliance; Additional Investor Directors
	  	 	18	  
	 Section 4.4
	  	 Resignation; Removal
	  	 	18	  
	 Section 4.5
	  	 Vacancies; New Directorships
	  	 	19	  
	 Section 4.6
	  	 Fees and Expenses
	  	 	19	  
	 Section 4.7
	  	 Board Observer
	  	 	19	  
	 Section 4.8
	  	 Committees; Subsidiary Boards
	  	 	19	  
	 Section 4.9
	  	 Reporting Information
	  	 	20	  
	 Section 4.10
	  	 Directors and Officers Insurance
	  	 	20	  
		
	 Article V Consent Rights
	  	 	20	  
	 Section 5.1
	  	 Investor Approval
	  	 	20	  
		
	 Article VI Information Rights
	  	 	23	  
	 Section 6.1
	  	 Delivery of Financial Statements
	  	 	23	  
	 Section 6.2
	  	 Reasonable Information
	  	 	24	  
		
	 Article VII Events of Default; Remedies
	  	 	24	  
	 Section 7.1
	  	 Events of Default
	  	 	24	  
	 Section 7.2
	  	 Remedies
	  	 	25	  

  
 i 

 Table of Contents 

(continued) 
  

							
	 	  	 	  	Page	 
	 Article VIII Miscellaneous
	  	 	25	  
	 Section 8.1
	  	 Expenses
	  	 	25	  
	 Section 8.2
	  	 Amendments and Waivers
	  	 	26	  
	 Section 8.3
	  	 Notices
	  	 	26	  
	 Section 8.4
	  	 Certain Tax Matters
	  	 	27	  
	 Section 8.5
	  	 Assignments and Transfers by Investors
	  	 	29	  
	 Section 8.6
	  	 Assignments and Transfers by the Company
	  	 	30	  
	 Section 8.7
	  	 Beneficiaries of the Agreement
	  	 	30	  
	 Section 8.8
	  	 Counterparts; Facsimiles and Electronic Copies
	  	 	30	  
	 Section 8.9
	  	 Titles and Subtitles
	  	 	30	  
	 Section 8.10
	  	 Severability
	  	 	30	  
	 Section 8.11
	  	 No Strict Construction
	  	 	30	  
	 Section 8.12
	  	 Further Assurances
	  	 	30	  
	 Section 8.13
	  	 Entire Agreement
	  	 	31	  
	 Section 8.14
	  	 Governing Law; Consent to Jurisdiction; Waiver of Jury Trial
	  	 	31	  

  
 ii 

 INVESTOR RIGHTS AGREEMENT 

This INVESTOR RIGHTS AGREEMENT (this “Agreement”) is made and entered into as of February 1, 2011 by and between
iGATE Corporation, a Pennsylvania corporation (the “Company”), and Viscaria Limited, a Cyprus private company limited by shares (the “Initial Investor”). Capitalized terms used but not otherwise defined in this
Agreement shall have the meanings ascribed to such terms in Article I. 
 WHEREAS, the Initial Investor is party to that
certain Securities Purchase Agreement, dated as of January 10, 2011 among the Company and the Initial Investor (as may be amended or modified in accordance with its terms from time to time, the “Purchase Agreement”); and

 WHEREAS, as a condition to the initial funding contemplated by the Purchase Agreement, the Initial Investor and the Company
have agreed to enter into this Agreement as of the date hereof. 
 NOW, THEREFORE, in consideration of the mutual promises made
herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows: 
 ARTICLE I 
 CERTAIN DEFINITIONS 

As used in this Agreement, the following terms shall have the following meanings. Any terms which refer to the Series B Statement are
hereby incorporated by reference hereto in all respects and shall maintain such definition even if such Preferred Stock is no longer outstanding. 
 “10% Holder” has the meaning set forth in Section 2.8. 
 “Additional Shares” has the meaning set forth in Section 2.1(b). 
 “Affiliate” means, (a) with respect to the Company or any Subsidiary of the Company, any other Person (other than the Subsidiaries of the Company or the Company) that directly or
indirectly through one or more intermediaries Controls, is Controlled by, or is under common Control with, such Person or (b) with respect to any other Person, any other Person that directly or indirectly through one or more intermediaries
Controls or is Controlled by, or is under common Control with, such Person. For the avoidance of doubt, each investment fund managed and/or advised by, or any other Person under common control with, Apax Partners LLP or any such investment fund
shall be deemed to be an Affiliate of the Initial Investor. 
 “Agreement” has the meaning set forth in the
preamble. 
 “Allowed Delay” has the meaning set forth in Section 2.2. 

“Audit Committee” means the audit committee of the Company. 

“Board” means the board of directors of the Company. 

“Board Threshold” shall have the meaning set forth in Section 4.1. 

“Business Day” means any day except Saturday, Sunday and any day on which banking institutions in the State of New York
or in the State of California generally are authorized or required by law or other governmental actions to close. 

“Change of Control” has the meaning set forth in the Series B Statement. 

 “Closing Financing Agreements” means the Loan Documents, as defined in the
Series B Statement. 
 “Closing Indebtedness” means the Indebtedness of the Company and its Subsidiaries
incurred under the Closing Financing Agreements in connection with the transactions contemplated in the Patni Purchase Agreements. 
 “Common Stock” means the Company’s common stock, par value $0.01 per share, and any securities into which such shares may hereinafter be reclassified. 

“Company” has the meaning set forth in the preamble. 

“Company Indemnified Person” has the meaning set forth in Section 2.7(b). 

“Company’s Knowledge” has the meaning set forth in the Purchase Agreement. 

“Competitor” has the meaning set forth in Section 3.6(a). 

“Control” (including the terms “Controlling”, “Controlled by” or “under common Control
with”) means the possession, direct or indirect, of the power to direct or cause the direction of the management and policies of a Person, whether through the ownership of voting securities, by contract or otherwise. 

“Conversion Stock” has the meaning set forth in the Series B Statement. 

“Convertible Securities” shall have the meaning set forth in the Series B Statement. 

“Cyprus-India Income Tax Treaty” means the 1994 Agreement Between the Republic of Cyprus and the Republic of India for
the Avoidance of Double Taxation and the Prevention of Fiscal Evasion with Respect to Taxes on Income and Capital. 

“Effectiveness Period” has the meaning set forth in Section 2.4(a)(i). 

“Event of Default” has the meaning set forth in Section 7.1. 

“Event of Noncompliance” has the meaning set forth in the Series B Statement. 

“Exchange Act” means the United States Securities Exchange Act of 1934, as amended, and the rules and regulations
promulgated thereunder. 
 “Filing Deadline” has the meaning set forth in Section 2.1(a).

 “Financing Proposal” has the meaning set forth in Section 3.1(c). 

“First Closing Date” has the meaning set forth in the Purchase Agreement. 

“GAAP” means United States generally accepted accounting principles, consistently applied, as in effect from time to
time. 
 “Indebtedness” has the meaning set forth in the Purchase Agreement. 

“Initial Investor” has the meaning set forth in the preamble. 

“Interim Funding” has the meaning set forth in the Purchase Agreement. 

“Investor Directors” has the meaning set forth in Section 4.1. 

“Investor Indemnified Person” has the meaning set forth in Section 2.7(a). 

  
 2 

 “Investors” means the Initial Investor and any Person who acquires all or
any portion of the Preferred Stock or the Conversion Stock following the First Closing Date in accordance with the terms of this Agreement. 
 “Key Shareholders” shall mean Sunil Wadhwani, Wadhwani Partners No. 1 LP, Wadhwani Partners No. 2 LP, Sunil and Nita Wadhwani Family Foundation, Ashok Trivedi and The Trivedi
Family Qualified Subchapter S Trust. 
 “Majority Sponsor Investors” means the Investors from time to time
holding at least a majority of the Preferred Stock (or Conversion Stock received upon conversion thereof) owned by the Sponsor Group. 
 “New Registration Statement” has the meaning set forth in Section 2.1(c). 
 “Options” has the meaning set forth in Series B Statement. 

“Patni” has the meaning set forth in the Purchase Agreement. 

“Patni Purchase Agreements” has the meaning set forth in the Purchase Agreement. 

“Permitted Dividend” has the meaning set forth in Section 5.1(a)(i). 

“Permitted Issuance” has the meaning set forth in Section 5.1(a)(ii). 

“Person” means any individual, corporation, partnership, limited liability company, trust, business trust, association,
joint stock company, joint venture, sole proprietorship, unincorporated organization, governmental authority or other form of entity not specifically listed in this definition. 

“Preferred Stock” means the Series B Preferred Stock. 

“Prospectus” means the prospectus included in any Registration Statement, as amended or supplemented by any prospectus
supplement, with respect to the terms of the offering of any portion of the Registrable Securities covered by such Registration Statement and by all other amendments and supplements to such prospectus, including post-effective amendments and all
material incorporated by reference in such prospectus. 
 “Purchase Agreement” has the meaning set forth in the
recitals to this Agreement. 
 “Purchase Rights” shall have the meaning set forth in Section 3.3.

 “Register,” “registered” and “registration” refer to a registration made
by preparing and filing a Registration Statement or similar document in compliance with the Securities Act, and the declaration or ordering of effectiveness of such Registration Statement or document. 

“Registrable Securities” means, collectively, (i) the Conversion Stock and (ii) any other securities issued or
issuable upon conversion of or in exchange for Registrable Securities; provided that as to any particular Registrable Security, such security shall cease to be a Registrable Security upon (A) sale pursuant to a Registration Statement or
Rule 144 under the Securities Act, or (B) such security becoming eligible for sale by the Investor pursuant to Rule 144(b)(i)(1). 
 “Registration Statement” means any registration statement of the Company filed under the Securities Act that covers the resale of any of the Registrable Securities pursuant to the
provisions of this Agreement, amendments and supplements to such registration statement, 

  
 3 

 
including post-effective amendments, all exhibits and all material incorporated by reference in such registration statement. 

“Related Party” means (i) any officer, director or 5% stockholder of the Company (which for such calculation shall
aggregate stockholdings of Affiliates, and immediate family members sharing the same household with such Persons), (ii) any officer or director of any of the Company’s Subsidiaries, or (iii) any member of any such Person’s
immediate family sharing the same household or any of their respective Affiliates. 
 “Remainder Registration
Statements” has the meaning set forth in Section 2.1(c). 
 “Restricted Payment” means:
(a) any dividend or other distribution, direct or indirect, on account of any shares of any class of stock of the Company or any of its Subsidiaries now or hereafter outstanding (other than (i) Permitted Dividends, (ii) dividends or
distributions payable to the Company or to any of its Subsidiaries or (iii) repurchases or redemptions by the Company or any of its Subsidiaries of the stock of their respective wholly-owned Subsidiaries); (b) except as permitted in clause
(a), any payment or prepayment of principal of, premium, if any, or interest on, or any repurchase, redemption, conversion, exchange, retirement, defeasance, sinking fund or similar payment, purchase or other acquisition for value, direct or
indirect, of any shares of any class of stock of the Company or any of its Subsidiaries now or hereafter outstanding; (c) any payment made to retire, or to obtain the surrender of, any outstanding warrants, Options or other rights to acquire
shares of any class of stock of the Company or any of its Subsidiaries now or hereafter outstanding (unless the terms thereof were approved by the Investor as set forth in Section 5.1, or exempted from such approval); and (d) any
payment by the Company or any of its Subsidiaries of any management, consulting or other fees to any Related Party, whether pursuant to a management agreement or otherwise, excluding compensation of officers, directors or employees of the Company
and its Subsidiaries; provided, that repurchases of equity securities issued to employees, officers, directors, consultants or other persons who performed services for the Company or its Subsidiaries in connection with the cessation of such
employment or service and pursuant to a pre-existing written agreement with such party permitting such a repurchase shall not constitute Restricted Payments. 
 “Rule 415” means Rule 415 promulgated by the SEC pursuant to the Securities Act, as such Rule may be amended from time to time, or any similar rule or regulation hereafter adopted by the
SEC having substantially the same effect as such Rule. 
 “SEC” means the United States Securities and Exchange
Commission. 
 “SEC Guidance” means (i) any publicly-available written guidance or interpretations of the
SEC staff and (ii) the Securities Act. 
 “Second Closing Date” means the Second Closing Date as defined
in the Purchase Agreement. 
 “Securities Act” means the United States Securities Act of 1933, as amended, and
the rules and regulations promulgated thereunder. 
 “Series B Preferred Stock” means the 8% Series B
Convertible Participating Preferred Stock, no par value per share, of the Company having the rights, preferences, limitations and special rights set forth in the Series B Statement, together with any securities into which such shares may be
reclassified. 

  
 4 

 “Series B Statement” means the Statement with Respect to Shares of Series B
Preferred Stock, in the form attached as Exhibit C to the Purchase Agreement. 
 “Settlement Date” has
the meaning set forth in the Series B Statement. 
 “Shareholder Approval” has the meaning set forth in the
Series B Statement. 
 “Shelf Registration Statement” has the meaning set forth in Section 2.1(a).

 “Sponsor Group” means the Initial Investor and its Affiliates; provided, that (i) during the
continuance of an Event of Noncompliance under Section 11(a)(i)(A) of the Series B Statement for payment defaults under Section 6(b) or Section 6(c) of the Series B Statement or (ii) if an Event of Noncompliance under
Section 11(a)(i)(A) of the Series B Statement for a payment default under Section 6(a) of the Series B Statement has occurred and is continuing for at least one year, the Sponsor Group shall also include any permitted transferee of the
Sponsor Group and such designation shall remain, even if such Event of Noncompliance following any such transfer is no longer continuing. 
 “Sponsor Investors” has the meaning set forth in Section 3.1(a). 
 “Sub Board” has the meaning set forth in Section 4.8. 

“Subsequent Financing” means any issuance of (x) equity securities of the Company or (y) debt securities of
the Company which are not solely current cash pay debt securities (other than pursuant to the Loan Documents as defined in the Purchase Agreement) that, in each case, is consummated by the Company (or any of its Subsidiaries, as applicable)
following the First Closing Date other than any issuance of (a) Common Stock issued in an underwritten public offering contemplated in Section 5.1(a)(ii)(8), (b) shares of Common Stock as consideration in a merger or
acquisition of the stock or assets of another Person so long as such merger or acquisition was consented to in accordance with, or did not require consent pursuant to, Section 5.1(a)(v), (c) grants of equity to officers, employees,
directors or consultants of the Company and its Subsidiaries pursuant to the Company’s written benefit plans, (d) securities issued pursuant to any rights agreements, including, without limitations, Convertible Securities, Options and
warrants, provided that either (i) the Company shall have complied with Section 3.1, Section 3.3 and Section 5.1(a)(ii), as applicable with respect to the initial sale or grant by the Company of such rights
or agreements, or (ii) such rights or agreements as are scheduled on Schedule 4.4(c) of the Disclosure Schedules to the Purchase Agreement that existed prior to the Company’s obligations under Section 3.1,
Section 3.3 and Section 5.1(a)(ii), (it being understood that any modification or amendment to any such pre-existing right or agreement subsequent to the date of this Agreement with the effect of increasing the percentage of
the Company’s fully-diluted securities underlying such rights agreement shall not be included in this clause (ii)), (e) upon the occurrence of a stock split, stock dividend or any subdivision of the Common Stock, and (f) any
right, option or warrant to acquire any securities convertible into the securities excluded from the definition of Subsequent Financing pursuant to clauses (a) through (e) above. For the avoidance of doubt, any debt
securities that involve an interest component that is not current pay, conversion into equity or provides for an equity component will be subject to the right of first offer provided for in Section 3.1 and unless a Permitted Issuance,
will also be subject to the preemptive rights provided for in Section 3.3, if applicable. 
 “Subsequent
Financing Notice” has the meaning set forth in Section 3.1(b). 

  
 5 

 “Subsidiary” shall mean any corporation, partnership, limited liability
corporation, joint venture, joint stock corporation, trust, unincorporated organization or other entity for which the Corporation owns at least 50% of the Voting Stock of such entity. 

“Termination Date” shall have the meaning set forth in Series B Statement. 

“Trading Market” shall have the meaning set forth in the Series B Statement. 

“Transaction Documents” means this Agreement, the Series B Statement, the Purchase Agreement, the Voting and Standstill
Agreement, the Patni Purchase Agreements and all other agreements delivered or required to be delivered by any party hereto pursuant to the Patni Purchase Agreements. 
 “Transfer Agent” has the meaning set forth in Section 2.4(b). 
 “Voting and Standstill Agreement” means that certain voting and standstill agreement by and among the Key Shareholders, the Company and the Initial Investor, executed as of the date of
the Purchase Agreement. 
 “Voting Securities” has the meaning set forth in Section 3.5(a).

 “Voting Stock” shall have the meaning set forth in the Series B Statement. 

ARTICLE II 

REGISTRATION RIGHTS 
 Section 2.1 Mandatory Registration. 
 (a) Demand Registration.
No later than nine months from the First Closing Date, (the “Filing Deadline”), the Company shall prepare and file with the SEC one Registration Statement on Form S-3 (or, if Form S-3 is not then available to the Company, then on
such form of registration statement as is then available to effect a registration for resale of the Registrable Securities), covering the resale of the Registrable Securities in an amount at least equal to the total number of shares of Conversion
Stock issuable upon conversion of all then outstanding shares of Series B Preferred Stock (assuming for the purposes of this calculation that Shareholder Approval had been obtained and assuming maximum accretion through the latest possible
Settlement Date) (the “Shelf Registration Statement”). The Shelf Registration Statement shall also cover, to the extent allowable under the Securities Act and the rules promulgated thereunder (including Rule 416), such indeterminate
number of additional shares of Common Stock resulting from stock splits, stock dividends, similar transactions or other adjustments provided for in the Series B Statement with respect to the Registrable Securities. The Shelf Registration Statement
shall not include any shares of Common Stock or other securities for the account of any other holder without the prior written consent of the holders of a majority of the Registrable Securities. Each Registration Statement (and each amendment or
supplement thereto, and each request for acceleration of effectiveness thereof) shall be provided in accordance with Section 2.4(a)(iii) to the Investors and their counsel prior to its filing or other submission. 

(b) Additional Registrable Securities. Within ten days of the written demand of any Investor and at such time as additional shares of
Common Stock (the “Additional Shares”) become issuable upon conversion of any Preferred Stock (whether due to an adjustment under 

  
 6 

 
the Statements With Respect to Shares or otherwise), the Company shall prepare and file with the SEC one or more Registration Statements on Form S-3 or amend the Shelf Registration Statement, as
applicable, if such Shelf Registration Statement has not previously been declared effective (or, if Form S-3 is not then available to the Company, then on such form of registration statement as is then available to effect a registration for resale
of such Additional Shares), covering the resale of the Additional Shares, but only to the extent the Additional Shares are not at the time covered by an effective Registration Statement. Such Registration Statement also shall cover, to the extent
allowable under the Securities Act and the rules promulgated thereunder (including Rule 416), such indeterminate number of additional shares of Common Stock resulting from stock splits, stock dividends or similar transactions with respect to the
Additional Shares. Such Registration Statement shall not include any shares of Common Stock or other securities for the account of any other holder without the prior written consent of the holders of a majority of the Registrable Securities.

 (c) Notwithstanding the registration obligations set forth in this Section 2.1, in the event that the SEC informs
the Company that all of the Registrable Securities may not, as a result of the application of Rule 415 or any other applicable securities law, rule or regulation, be registered for resale as a secondary offering on a single registration statement,
the Company agrees to (i) promptly inform each of the Investors thereof, and (ii) use all reasonable best efforts to promptly file amendments to the Shelf Registration Statement, as applicable, as required by the Commission and/or
(iii) promptly withdraw the Shelf Registration Statement and promptly file a new registration statement (a “New Registration Statement”), in either case, covering the maximum number of Registrable Securities permitted to be
registered by the SEC, on Form S-3 or such other form available to register for resale the Registrable Securities as a secondary offering; provided, however, that prior to filing such amendment or New Registration Statement, the
Company shall be obligated to use all reasonable best efforts to advocate with the SEC for the registration of all of the Registrable Securities in accordance with the SEC Guidance. In the event that the Company amends the Shelf Registration
Statement or files a New Registration Statement, as the case may be, under clauses (ii) or (iii) above, the Company will use all reasonable best efforts to file with the SEC, as promptly as allowed by the SEC or the SEC Guidance provided
to the Company or to registrants of securities in general, one or more registration statements on Form S-3 or such other form available to register for resale those Registrable Securities that were not registered for resale on the Shelf Registration
Statement, as amended, or the New Registration Statement (the “Remainder Registration Statements”). 

Section 2.2 Allowed Delay. For not more than thirty consecutive days (or forty-five consecutive days if neither the Initial
Investor nor an Affiliate of an Initial Investor owns any of the Registrable Securities) or for a total of not more than sixty days in any twelve-month period (or ninety days in any twelve-month period, if neither the Initial Investor nor Affiliate
of an Initial Investor owns any of the Registrable Securities), the Company may suspend the use of any Prospectus included in any registration statement contemplated by this Article II if such use would require the disclosure of material
non-public information concerning the Company, the disclosure of which at the time is not, in the good faith opinion of the Board, in the best interests of the Company (an “Allowed Delay”); provided that the Company shall
(a) promptly notify the Investors in writing of the suspension (but in no event, without the prior written consent of an Investor, shall the Company disclose to such Investor any of the facts or circumstances regarding the material non-public
information giving rise to an Allowed Delay), and (b) promptly advise 

  
 7 

 
the Investors in writing to cease all sales under any Registration Statement until the end of the Allowed Delay and (c) use reasonable best efforts to terminate an Allowed Delay as promptly
as practicable when the use of the Prospectus would not require the disclosure of material non-public information. 

Section 2.3 Expenses. The Company will pay all expenses incurred by the Company in connection with the registrations
contemplated by this Article II, including filing and printing fees, the Company’s counsel and accounting fees and expenses, costs associated with registering the Registrable Securities for sale under applicable state securities laws,
listing fees, but in no event will the Company be responsible for any fees or expenses or transfer taxes of any holder of Registrable Securities, or underwriting discounts, selling commissions or similar fees of any underwriters, selling brokers,
dealer managers or similar securities industry professionals with respect to the Registrable Securities being sold. 

Section 2.4 Company Obligations. 
 (a) The Company shall use all reasonable best efforts to effect the registration of the Registrable Securities in accordance with the terms hereof, and pursuant thereto the Company will, as expeditiously
as practicable: 
 (i) use all reasonable best efforts to cause such Registration Statement to become effective and to remain
continuously effective in accordance with Section 2.1(a) for a period that will terminate upon the earlier of (x) the date on which all Registrable Securities covered by such Registration Statement have been sold, and (y) the
date on which there are no longer any Registrable Securities outstanding (the “Effectiveness Period”), and advise the Investors in writing when the Effectiveness Period has expired; 

(ii) use all reasonable best efforts to prepare and file with the SEC such amendments and post-effective amendments to each Registration
Statement and the Prospectus used in connection therewith as may be necessary to keep such Registration Statement continuously effective, supplemented and amended for the Effectiveness Period and to comply with the provisions of the Securities Act
and the Exchange Act with respect to the distribution of all of the Registrable Securities covered thereby; 
 (iii) provide
copies to and permit counsel designated by the Investors to review each Registration Statement and all amendments and supplements thereto (other than reports and proxy statements filed by the Company under the Exchange Act that are incorporated by
reference in the Registration Statement or the Prospectus) no fewer than seven days prior to their filing with the SEC and, except as required by law, not file any document to which such counsel reasonably objects in good faith (other than reports
and proxy statements filed by the Company under the Exchange Act that are incorporated by reference in the Registration Statement or the Prospectus); 
 (iv) furnish to the Investors and their legal counsel (A) promptly after the same is prepared and publicly distributed, filed with the SEC, or received by the Company (but not later than two Business
Days after the filing date, receipt date or sending date, as the case may be) one copy of each Registration Statement and any amendment thereto, each preliminary 

  
 8 

 
prospectus, free-writing prospectus and Prospectus and each amendment or supplement thereto, and each letter written by or on behalf of the Company to the SEC or the staff of the SEC, and each
item of correspondence from the SEC or the staff of the SEC, in each case, relating to such Registration Statement (other than any portion thereof which contains information for which the Company has sought confidential treatment), and (B) such
number of copies of a Prospectus, including a preliminary prospectus, any free-writing prospectus and all amendments and supplements thereto and such other documents as each Investor may reasonably request in order to facilitate the disposition of
the Registrable Securities owned by such Investor that are covered by each Registration Statement; 
 (v) in the event the
holders of a majority of the Registrable Securities request that the Company participate in any underwritten public offering of the Conversion Stock, the Company shall enter into and perform its obligations under an underwriting agreement, in usual
and customary form, with the managing underwriter(s) of such offering selected by the holders of a majority of the Registrable Securities. Each Investor participating in such underwriting shall also enter into and perform its obligations pursuant to
such an agreement; 
 (vi) use all reasonable best efforts to (A) prevent the issuance of any stop order or other
suspension of effectiveness of a Registration Statement and, (B) if such order is issued, obtain the withdrawal of any such order at the earliest possible moment; 
 (vii) prior to any public offering of Registrable Securities, use all reasonable best efforts to register or qualify or cooperate with the Investors and their counsel in connection with the registration
or qualification (or exemption from such registration or qualification) of such Registrable Securities for offer and sale under the securities or blue sky laws of such jurisdictions requested by the Investors and do any and all other acts or things
reasonably necessary or advisable to enable the distribution in such jurisdictions of the Registrable Securities covered by each Registration Statement; provided, however, that the Company shall not be required in connection therewith
or as a condition thereto to (A) qualify to do business in any jurisdiction where it would not otherwise be required to qualify but for this Section 2.4(a)(vii), (B) subject itself to general taxation in any jurisdiction where
it would not otherwise be so subject but for this Section 2.4(a)(vii), or (C) file a general consent to service of process in any such jurisdiction; 
 (viii) use all reasonable best efforts to cause all Registrable Securities covered by each Registration Statement to be listed on each securities exchange, interdealer quotation system or other market on
which similar securities issued by the Company are then listed; 
 (ix) promptly notify the Investors, at any time when a
Prospectus relating to Registrable Securities is required to be delivered under the Securities Act (including during any period when the Company is in compliance with Rule 172), upon discovery that, or upon the happening of any event as a result of
which, the Prospectus included in a Registration Statement, as then in effect, includes an untrue statement of a material fact or omits to state any material fact required to be stated therein or necessary to make the statements therein not
misleading in light of the circumstances then existing, and at the reasonable request of any Investor and if required by applicable law, promptly prepare, file with the SEC pursuant to Rule 172 and furnish to such Investor a supplement to or an
amendment of such Prospectus as may be necessary so that such 

  
 9 

 
Prospectus shall not include an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading in
light of the circumstances then existing; 
 (x) otherwise use all reasonable best efforts to comply with all applicable rules
and regulations of the SEC under the Securities Act and the Exchange Act and take such other actions as may be reasonably necessary to facilitate the registration of the Registrable Securities hereunder; and 

(xi) use all reasonable best efforts to take all other steps necessary or reasonably required to effect the registration of the
Registrable Securities covered by each Registration Statement contemplated hereby. 
 (b) Upon the earlier of (i) resale
pursuant to a Registration Statement, (ii) Rule 144 becoming available, (iii) any sale pursuant to Rule 144 or (iv) such time as a legend is no longer required under applicable requirements of the Securities Act (including controlling
judicial interpretations and pronouncements issued by the SEC), at the Investor’s request, the Company shall use all reasonable best efforts to (A) deliver to the transfer agent for the Common Stock (the “Transfer Agent”)
irrevocable instructions that the Transfer Agent shall reissue a certificate representing shares of Common Stock without legends upon receipt by such Transfer Agent of the legended certificates for such shares, together with either (1) a
customary representation by each Investor that such shares may be disposed of pursuant to Rule 144 or (2) in connection with any sale of Common Stock by the Investors pursuant to the registration contemplated by this Agreement and
(B) cause its counsel to deliver to the Transfer Agent one or more blanket opinions to the effect that the removal of such legends in such circumstances may be effected under the Securities Act. From and after the earlier of such dates, upon
the holders of a majority of the Registrable Securities written request, the Company shall promptly cause certificates evidencing the Conversion Stock to be replaced with certificates which do not bear such restrictive legends, and Conversion Stock
subsequently issued shall not bear such restrictive legends provided the provisions of either clause (i) or clause (ii) above, as applicable, are satisfied with respect to such Conversion Stock. 

(c) With a view to making available to the Investors the benefits of Rule 144 (or any successor rule) the Company agrees to:
(i) make and keep public information available, as those terms are understood and defined in Rule 144, until the earlier of (A) six months after such date as all of the Registrable Securities may be resold pursuant to Rule 144 or any other
rule of similar effect or (B) such date as all of the Registrable Securities shall have been resold; (ii) file with the SEC in a timely manner all reports and other documents required of the Company under the Exchange Act; and
(iii) furnish to each Investor upon request, as long as such Investor owns any Registrable Securities, (A) a written statement by the Company that it has filed all reports and documents required to be filed by the Company under the
Exchange Act, (B) a copy of the Company’s most recent Annual Report on Form 10-K or Quarterly Report on Form 10-Q; provided, that the Company shall have no obligation to provide any document pursuant to this clause that is available on the
SEC’s EDGAR system. 
 Section 2.5 Due Diligence Review; Information. 

  
 10 

 (a) In connection with any underwritten public offering consented to by the Company as
provided herein, upon reasonable prior notice and execution of a customary confidentiality agreement by the Investors, the Company shall make available, during normal business hours, for inspection and review by the Investors, any managing
underwriters and any attorneys or accountants retained by such Investors or managing underwriters, all financial and other records and all other pertinent documents of the Company as may be reasonably necessary for the purpose of such review, and
cause the Company’s officers, directors and employees, within a reasonable time period, to supply all such information reasonably requested by the Investors or any such representative, advisor or underwriter in connection with an underwritten
public offering pursuant to a Registration Statement (including in response to all questions and other inquiries reasonably made or submitted by any of them), prior to and from time to time after the filing and effectiveness of such Registration
Statement in connection with such underwritten public offering for the sole purpose of enabling the Investors and such representatives, advisors and underwriters and their respective accountants and attorneys to conduct a due diligence investigation
with respect to the Company and the accuracy of such Registration Statement. 
 (b) The Company shall not disclose material
nonpublic information to the Investors, or to advisors to or representatives of the Investors, unless prior to disclosure of such information the Company identifies such information as being material nonpublic information and provides the Investors,
such advisors and representatives with the opportunity to accept or refuse to accept such material nonpublic information for review and any Investor wishing to obtain such information enters into an appropriate confidentiality agreement with the
Company with respect thereto; provided, that the foregoing shall not restrict the Company from disclosing material non-public information to any Investor Director or Investor board observer, or to their advisors or representatives.

 Section 2.6 Obligations of the Investors. 

(a) Each Investor shall promptly furnish in writing to the Company such information regarding itself and the Registrable Securities held
by it as shall be reasonably required to effect the registration of such Registrable Securities and shall execute such documents in connection with such registration as the Company may reasonably request. At least ten Business Days prior to the
first anticipated filing date of each Registration Statement, the Company shall notify each Investor of the information the Company requires from such Investor. 
 (b) Each Investor, by its acceptance of the Registrable Securities agrees to cooperate with the Company as reasonably requested by the Company in connection with the preparation and filing of any
Registration Statement hereunder, unless such Investor has notified the Company in writing of its election to exclude all of its Registrable Securities from such Registration Statement. 

(c) Each Investor agrees that, upon receipt of any notice from the Company of either (i) the commencement of an Allowed Delay
pursuant to Section 2.2 or (ii) the happening of an event pursuant to Section 2.4(a)(ix), such Investor will immediately discontinue disposition of Registrable Securities pursuant to any Registration Statement covering
such Registrable Securities, until the Investor is advised by the Company that a supplemented or amended Prospectus has been filed with the SEC and until any related post-effective amendment is

  
 11 

 
declared effective and, if so directed by the Company, then the Investor shall deliver to the Company or destroy (and deliver to the Company a certificate of destruction) all copies in such
Investor’s possession of the Prospectus covering the Registrable Securities current at the time of receipt of such notice. 

Section 2.7 Indemnification. 
 (a) Indemnification by the Company. The Company agrees to indemnify and hold harmless each Investor and its affiliates and their respective directors, officers, members, shareholders, partners,
employees, affiliates, representatives and agents, each Person who Controls the Investor (within the meaning of Section 15 of the Securities Act and Section 20 of the Exchange Act), and the directors, officers, members, partners,
employees, affiliates, representatives and agents of such Controlling Person (each, an “Investor Indemnified Person”) from and against, without duplication, any and all losses, claims, damages, liabilities, contingencies and
expenses (including reasonable attorneys’ fees and disbursements and other expenses incurred in connection with investigating, preparing or defending any action, claim or proceeding, pending or threatened and the costs of enforcement thereof)
to which such Investor Indemnified Person may become subject caused by, as a result of, arising out of, based upon or relating to: (i) any untrue statement or alleged untrue statement of any material fact contained in any Registration
Statement, any preliminary Prospectus or final Prospectus contained therein, or any amendment or supplement thereof; or (ii) the omission or alleged omission to state therein a material fact required to be stated therein or necessary to make
the statements therein not misleading; provided, however, that the Company will not be liable to an Investor pursuant to this Section 2.7 if and to the extent that any such loss, claim, damage, liability, contingency or
expense arises out of or is based upon any untrue statement or alleged untrue statement or omission or alleged omission so made in conformity with information furnished by such Investor in writing specifically for use in such Registration Statement
or Prospectus. In connection with any underwritten offering, the Company will also indemnify the underwriters, if any, their respective Affiliates and each Person who Controls such Persons (within the meaning of the Securities Act and the Exchange
Act) to the same extent as provided above with respect to the indemnification of the Investor, if requested in connection with any Registration Statement, or any Prospectus. 
 (b) Indemnification by the Investors. Each Investor agrees, severally but not jointly, to indemnify and hold harmless the Company and its Affiliates and their respective directors, officers,
members, shareholders, partners, employees, affiliates, representatives and agents, each Person who Controls the Company (within the meaning of Section 15 of the Securities Act and Section 20 of the Exchange Act), and the directors,
officers, members, partners, employees, affiliates, representatives and agents (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding a lack of such title or any other title) of such Controlling
Person (each, a “Company Indemnified Person”) from and against, without duplication, any and all losses, claims, damages, liabilities, contingencies and expenses (including reasonable attorneys’ fees and disbursements and other
expenses incurred in connection with investigating, preparing or defending any action, claim or proceeding, pending or threatened and the costs of enforcement thereof) to which such Company Indemnified Person may become subject caused by, as a
result of, arising out of, based upon or relating to (i) any untrue statement of a material fact contained in any Registration Statement, any preliminary 

  
 12 

 
Prospectus or final Prospectus contained therein, or any amendment or supplement thereof, or (ii) the omission or alleged omission to state therein a material fact required to be stated
therein or necessary to make the statements therein not misleading, to the extent, but only to the extent that such untrue statement or omission is contained in any information furnished in writing by such Investor to the Company specifically for
inclusion in such Registration Statement, any preliminary Prospectus or final Prospectus contained therein, or any amendment or supplement thereof. In no event shall the liability of any Investor be greater in amount than the dollar amount of the
proceeds (net of all expense paid by such Investor in connection with any claim relating to this Section 2.7 and the amount of any damages such Investor has otherwise been required to pay by reason of such untrue statement or omission)
received by such Investor upon the sale of the Registrable Securities included in any Registration Statement giving rise to such indemnification obligation. 
 (c) Conduct of Indemnification Proceedings. Any Person entitled to indemnification hereunder shall (i) give prompt notice to the indemnifying party of any claim with respect to which it seeks
indemnification and (ii) permit such indemnifying party to assume the defense of such claim with counsel reasonably satisfactory to the indemnified party and the payment of all fees and expenses incurred in connection with the defense thereof;
provided that any Person entitled to indemnification hereunder shall have the right to employ separate counsel and to participate in the defense of such claim, but the fees and expenses of such counsel shall be at the expense of such Person
unless (A) the indemnifying party has agreed in writing to pay such fees or expenses, or (B) the indemnifying party shall have failed to assume the defense of such claim and employ counsel reasonably satisfactory to such Person or
(C) in the reasonable judgment of any such Person, based upon written advice of its counsel, a conflict of interest exists between such Person and the indemnifying party with respect to such claims (in which case, if the Person notifies the
indemnifying party in writing that such Person elects to employ separate counsel at the expense of the indemnifying party, then the indemnifying party shall not have the right to assume the defense of such claim on behalf of such Person); and
provided, further, that the failure of any indemnified party to give notice as provided herein shall not relieve the indemnifying party of its obligations hereunder, except to the extent such failure to give notice shall materially and
adversely prejudice the indemnifying party in the defense of any such claim or litigation. It is understood that the indemnifying party shall not, in connection with any proceeding in the same jurisdiction, be liable for fees or expenses of more
than one separate firm of attorneys at any time for all such indemnified parties. No indemnifying party will, except with the consent of the indemnified party, consent to entry of any judgment or enter into any settlement that does not include as an
unconditional term thereof the giving by the claimant or plaintiff to such indemnified party of a release from all liability in respect of such claim or litigation. 
 (d) Contribution. If for any reason the indemnification provided for in Section 2.7(a) and Section 2.7(b) is unavailable to an indemnified party or insufficient to hold it
harmless, other than as expressly specified therein, then the indemnifying party shall contribute to the amount paid or payable by the indemnified party as a result of all such losses, claims, damages, liabilities, contingencies and expenses
(including reasonable attorneys’ fees and disbursements and other expenses incurred in connection with investigating, preparing or defending any action, claim or proceeding, pending or threatened and the costs of enforcement thereof) in such
proportion as is appropriate to reflect the relative fault of the indemnified party and the 

  
 13 

 
indemnifying party, as well as any other relevant equitable considerations. No Person guilty of fraudulent misrepresentation within the meaning of Section 11(f) of the Securities Act shall
be entitled to contribution from any Person not guilty of such fraudulent misrepresentation. In no event shall the contribution obligation of any Investor be greater in amount than the dollar amount of the proceeds (net of all expenses paid by such
Investor in connection with any claim relating to this Section 2.7 and the amount of any damages such Investor has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission)
received by such Investor upon the sale of the Registrable Securities giving rise to such contribution obligation. 

Section 2.8 Applicability. The provisions of this Article II shall inure to any Investor or group of Investors who are
Affiliates of each other holding at least 10% of the Registrable Securities (on an as-converted basis) issued as of the Second Closing Date (or the First Closing Date if such Second Closing Date has not yet occurred) (each a “10%
Holder”). 
 ARTICLE III 
 OTHER RIGHTS 
 Section 3.1 Right of First Offer. 

(a) From and after the First Closing Date, the Investors who are members of the Sponsor Group owning no less than fifty percent
(50%) of the Conversion Stock issued or issuable upon the conversion of the Preferred Stock as of the Second Closing Date (or the First Closing Date, if the Second Closing Date has yet to occur) (assuming that, notwithstanding anything to the
contrary contained in Section 8(a) of the Series B Statement, each share of the Preferred Stock is convertible on the Second Closing Date or the First Closing Date, as the case may be) (whether or not such Conversion Stock has been issued or is
held through Preferred Stock or as a combination thereof and including for these purposes the benefit to the Investor of any accrual on any Preferred Stock before the Second Closing Date but disregarding for these purposes any accrual on any
Preferred Stock after the Second Closing Date) (the “Sponsor Investors”) shall have the right, at the election of the Majority Sponsor Investors in accordance with this Section 3.1, to participate in any Subsequent
Financing, subject to compliance with principal Trading Market, Securities Act and other restrictions required by applicable law; provided, that the Company shall use all reasonable best efforts to effectuate such compliance. The Majority
Sponsor Investors may elect to provide all or any portion of the Subsequent Financing in accordance with the provisions set forth below and such Subsequent Financing may be allocated among the Sponsor Investors in any manner such Sponsor Investors
(or their respective designees) shall determine. 
 (b) The Company shall deliver a written notice (each, a “Subsequent
Financing Notice”) to the Sponsor Group. The Subsequent Financing Notice shall include the type, amount and basic terms of the Subsequent Financing the Company is seeking to obtain. The Subsequent Financing Notice requirement shall be
deemed satisfied if the specifics of such Subsequent Financing were specifically discussed at a properly called and constituted Board meeting at which an Investor Director was present for such discussion. 

  
 14 

 (c) The Majority Sponsor Investors shall have 15 days to propose in writing to the Company
detailed terms for such Subsequent Financing (the “Financing Proposal”), or to decline the right to participate in such Subsequent Financing. 
 (d) The Company may, for a period of 180 days after receipt of the Financing Proposal from the Investors, attempt to obtain the financing requested in the Subsequent Financing Notice from other sources on
terms taken as a whole that are more favorable to the Company than the terms proposed by the Majority Sponsor Investors in the Financing Proposal; provided, that the Company shall provide the Sponsor Investors (or the Investor Directors)
every forty-five days while the Company continues to pursue such Subsequent Financing, an update as to the status of the Subsequent Financing, through meetings of the Board or otherwise. The Company may obtain such Subsequent Financing from such
alternative source if such Subsequent Financing can actually be effectuated on terms more favorable to the Company than the terms proposed by the Majority Sponsor Investors in the Financing Proposal; provided, that such financing must be
effectuated within 180 days of the date of the Majority Sponsor Investors’ Financing Proposal, and otherwise such Subsequent Financing must be reoffered to the Investors in accordance with the procedures set forth in this
Section 3.1. 
 Section 3.2 Due Diligence in Connection with Subsequent Financings. Upon the execution
of a confidentiality agreement (to the extent such Persons are not already bound by an obligation of confidentiality to the Company), the Company will provide the Majority Sponsor Investors with such information as they reasonably request that is
pertinent to any such Subsequent Financing. 
 Section 3.3 Preemptive Rights. If at any time the Company grants,
issues or sells any Common Stock, Options or any other Convertible Securities (other than a Permitted Issuance) to any Person (the “Purchase Rights”) then the Investors who are members of the Sponsor Group owning no less than fifty
percent (50%) of the Conversion Stock issued or issuable upon conversion of the Preferred Stock as of the Second Closing Date (or the First Closing Date if the Second Closing Date has yet to occur) (assuming, notwithstanding anything to the
contrary contained in Section 8(a) of the Series B Statement, each share of the Preferred Stock is convertible on the Second Closing Date or the First Closing Date, as the case may be) (whether or not such Conversion Stock has been issued or is
held through Preferred Stock or as a combination thereof and including for these purposes the benefit to the Investor of any accrual on an Preferred Stock before the Second Closing Date but disregarding for these purposes any accrual on any
Preferred Stock after the Second Closing Date) shall be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which shall result in such holder retaining the same proportionate share of the Common
Stock of the Company on a fully-diluted as-converted basis as prior to the grant, issuance or sale (assuming for this calculation that Shareholder Approval has been obtained and all shares of Preferred Stock are convertible into Conversion Stock).
The Company shall provide written notice of such grant, issuance or sale of Purchase Rights to each Investor, at least 15 days before such Investor shall be required to indicate its intent to exercise its preemptive rights. Only in the case of
underwritten public offerings (i) shall there be deemed notice to the Investor if the topic of the issuance triggering the preemptive right is specifically discussed at a Board meeting where an Investor Director is present for such discussion,
and otherwise such notice must be written, and (ii) once the notice provided in (i) is given with respect to the possibility of an underwritten 

  
 15 

 
public offering, any further communication to Investor regarding the “book build” for the public offering can be oral and given at the time of the “book build,” whenever it
may occur. Any notice with respect to this Section 3.3 shall not constitute notice for the purpose Section 3.1. For the avoidance of doubt, the preemptive rights of this Section 3.3 are separate and distinct from
the right of first offer in Section 3.1 and each Investor retains its preemptive rights even if the right of first offer is not elected. 
 Section 3.4 Additional Rights. Notwithstanding any other provision of this Article III, if the Subsequent Financing or the Purchase Right consists of an issuance of voting securities or
securities exercisable for or convertible into voting securities of the Company, and the Shareholder Approval has not been obtained, or any additional shareholder approval is required by the rules and regulations of the Trading Market on which the
Company’s securities are then listed in order to fully effectuate the Investor’s rights under Section 3.1 or Section 3.3 hereto, the Company shall make available to each Investor, at such Investor’s request,
non-voting securities which are otherwise identical to the voting securities and are convertible into voting securities at the request of the holder of such non-voting security, but only if permitted by the Company’s articles of incorporation
and bylaws; provided, that the Company shall use all reasonable best efforts to make any amendments required to effectuate such request. 
 Section 3.5 Voting. 
 (a) Shares subject to Voting Agreement. So
long as no Event of Default under this Agreement or Event of Noncompliance under the Series B Statement occurs or is continuing, each Investor hereby agrees to vote all of its shares of Series B Preferred Stock that are entitled to vote with the
Common Stock and any Conversion Stock issued upon conversion thereof, whether now owned or hereafter acquired (collectively, the “Voting Securities”), in accordance with this Section 3.5. 

(b) Voting Agreement as to Certain Matters. In connection with any proposal submitted for Company shareholder approval (at any
annual or special meeting called, or in connection with any other action (including the execution of written consents)) related to the election or removal of directors of the Board, each Investor will vote all of its Voting Securities as follows:

 (i) in favor of any independent or management nominee for director designated by the nominating or other applicable
committee of the Board (provided that the nominating committee’s designation is consistent with the terms of the Series B Statement and this Agreement); and 
 (ii) against the removal of any director designated in accordance with Section 3.5(b)(i). 
 (c) Termination of Voting Agreement. The provisions of this Section 3.4 shall terminate upon the earliest to occur of any one of the following events: 

(i) the date on which the Sponsor Group no longer beneficially owns, in the aggregate, Conversion Stock equal to at least the Board
Threshold; 

  
 16 

 (ii) the liquidation, dissolution or indefinite cessation of the business operations of the
Company; 
 (iii) the execution by the Company of a general assignment for the benefit of creditors or the appointment of a
receiver or trustee to take possession of the property and assets of the Company; or 
 (iv) a Change of Control of the
Company. 
 Section 3.6 Transfers. 
 (a) Each Investor hereby agrees that it will not at any time directly or knowingly indirectly (without any duty of investigation) transfer any shares of Preferred Stock to any Competitor of the Company
other than during the existence of an Event of Noncompliance under Section 11(a)(i)(A) occurring under Section 6(a) of the Series B Statement. For purposes of this Section 3.6, “Competitor” shall mean any
Person whose primary business is information technology services with annual revenues from such information technology services of more than $100 million; provided that financial investors who hold investments in one or more Persons in the
business of information technology services shall not be deemed a Competitor of the Company. 
 (b) Reasonable
Cooperation. The Company shall provide reasonable cooperation in connection with potential transfers (including allowing access to diligence for potential transferees other than to Competitors) upon reasonable notice, subject to the potential
transferee entering into a customary confidentially agreement. 
 Section 3.7 Standstill. Each Investor shall not,
and shall cause its Affiliates to not, whether acting alone or in concert with others: 
 (a) pursue a hostile tender offer for
the Company’s Common Stock; provided, that, for the avoidance of doubt, the foregoing should not prevent the Investors from pursuing a going-private transaction approved by the Board; 

(b) enter into a short position with respect to the Company’s stock; or 

(c) publicly disclose any intention, plan or arrangement inconsistent with the terms of this Section 3.7. 

ARTICLE IV 

NOMINATION OF INVESTOR DIRECTORS 
 Section 4.1 Investor Directors. So long as the Sponsor Group beneficially owns, in the aggregate, at least one third of the Conversion Stock issued or issuable upon conversion of the Preferred
Stock as of the Second Closing Date (assuming that, notwithstanding anything to the contrary contained in Section 8(a) of the Series B Statement, each share of the Preferred Stock is convertible on the Second Closing Date or the First Closing
Date, as the case may be) (whether or not such Conversion Stock has been issued or is held through the Preferred Stock or 

  
 17 

 
as a combination thereof and including for these purposes the benefit to the Investor of any accrual on any Preferred Stock before the Second Closing Date but disregarding for these purposes any
accrual on any Preferred Stock after the Second Closing Date) (the “Board Threshold”), the Majority Sponsor Investors may nominate one director if the total number of directors of the Company is nine or less, and two directors if
the total number of directors of the Company is ten or more (for so long as the right to elect such additional director is consistent with Nasdaq Listing Rule 5640) to the Board (the “Investor Directors”). Each Investor Director
appointed pursuant to this Section 4.1 shall, subject to the Board Threshold, continue to hold office until such Investor Director’s term expires, subject, however, to prior death, resignation, retirement, disqualification or
termination of term of office as provided in Section 4.4. 
 Section 4.2 Continuing Designation of
Investor Directors. Subject to the Board Threshold, at each meeting of the Company’s stockholders at which the election of directors is to be considered, the Company shall nominate the Investor Director(s) designated by the Majority Sponsor
Investors for election to the Board by the holders of Voting Stock and solicit proxies from the Company’s stockholders in favor of the election of Investor Directors. The Company shall use all reasonable best efforts to cause each Investor
Director to be elected to the Board (including voting all unrestricted proxies in favor of the election of such Investor Director and including recommending approval of such Investor Director’s appointment to the Board) and shall not take any
action designed to diminish the prospects of such Investor Director(s) of being elected to the Board. 
 Section 4.3
Event of Noncompliance; Additional Investor Directors. Subject to the Board Threshold, the Majority Sponsor Investors shall have the right to nominate (and the Company shall take all reasonably necessary actions such as causing the size of
the Board to be increased accordingly or a non-Investor Director or Directors to resign to vacate a Board seat to permit such nomination) two additional members of the Board in the event that there is an Event of Noncompliance under
Section 11(a)(i)(A) of the Series B Statement and such additional directors shall remain seated during the pendency of such Event of Noncompliance and shall be automatically removed when an Event of Noncompliance under Section 11(a)(i)(A)
is no longer continuing. Such director(s) shall be nominated and elected in accordance with this Article IV and Section 7.2, and each such director shall be deemed an Investor Director for all purposes of this Article IV,
and such additional directors shall have additional proportionate rights to serve on committees of the Board, Sub Boards and Sub Board committees commensurate with Section 4.8, so long as consistent with the independence and other
applicable requirements of the principal Trading Market of the Company’s Common Stock or under applicable law; provided, that the Company shall use all reasonable best efforts to effectuate such compliance. 

Section 4.4 Resignation; Removal. 
 (a) Resignation. Any elected Investor Director may resign from the Board at any time by giving written notice to the Company at its principal executive office. Unless otherwise required by law, the
resignation is effective without acceptance when the notice is given to the Company, unless a later effective time is specified in the notice. 

  
 18 

 (b) Removal. The Company shall use all reasonable best efforts consistent with
providing that any Investor Director is removed only if so directed in writing by the Majority Sponsor Investors, unless otherwise required by applicable law. 
 Section 4.5 Vacancies; New Directorships. In the event of a vacancy on the Board resulting from the death, disqualification, resignation, retirement or termination of term of office of an
Investor Director or the creation of a new directorship to which the Majority Sponsor Investor has the right to nominate a director as provided in this Article IV, then the Company shall use all reasonable best efforts to cause the Board to
fill such vacancy or new directorship with a representative designated by the Majority Sponsor Investors as provided hereunder, in either case, to serve until the next annual or special meeting of the stockholders (and at such meeting, such
representative, or another representative designated by such holders, will be elected to the Board in the manner set forth in Section 4.2). If the Majority Sponsor Investors fail or decline to fill the vacancy, then the directorship
shall remain open until such time as the Majority Sponsor Investors elect to fill it with a representative designated hereunder. During any such period that the Majority Sponsor Investors are entitled to, but have failed or declined to, designate
any Investor Director, the Majority Sponsor Investors shall have the right to designate one additional representative to attend all Board meetings as a non-voting observer. Such observer shall be entitled to notice of all Board meetings in the
manner that notice is provided to members of the Board, shall be entitled to receive all materials provided to members of the Board, at the same time as provided to members of the Board and shall be entitled to attend (whether in person, by
telephone, or otherwise) all meetings of the Board as a non-voting observer. 
 Section 4.6 Fees and Expenses. The
Investor Directors appointed pursuant to Section 4.5 and any Board Observer designated pursuant to Section 4.7 shall be entitled to reimbursement of expenses incurred in such capacities on the same basis as the Company
provides such reimbursement to the other members of its Board. 
 Section 4.7 Board Observer. Subject to the Board
Threshold, in addition to any observer designated pursuant to Section 4.5 above, the Majority Sponsor Investors shall at all times have the right to designate one non-voting observer to attend Board meetings as an observer. The observer
shall be entitled to notice of all Board and committee meetings in the manner that notice is provided to members of the Board, shall be entitled to receive all materials provided to members of the Board and committees, at the same time as provided
to members of the Board and such committees and shall be entitled to attend (whether in person, by telephone, or otherwise) all meetings as a non-voting observer. 
 Section 4.8 Committees; Subsidiary Boards. Subject to the Board Threshold, the Company shall use its reasonable best efforts such that one of the Investor Directors shall be a member of each
committee of the Board other than the Audit Committee, so long as consistent with the independence and other applicable requirements of the principal Trading Market of the Company’s Common Stock or under applicable law; provided, that
the Company shall use all reasonable best efforts to effectuate such compliance; and provided further, that one Investor Director may participate as an observer to the Audit Committee and shall have the observer rights set forth in
Section 4.7. Any committee of the Board may, at its reasonable discretion, exclude from such committee meeting any observer attending such meeting in accordance with 

  
 19 

 
this Section 4.8 or Section 4.7. At the request of the Majority Sponsor Investors, the Company shall cause the Investor Directors to have proportional representation
(relative to their percentage on the whole Board, but in no event less than one representative) on the boards (or equivalent governing body) of each publicly-traded Subsidiary of the Company (or in the case of a continuing Event of Noncompliance,
any Subsidiary of the Company) (each, a “Sub Board”). Subject to the Board Threshold, one Investor representative shall be seated on the Patni board of directors and an additional Investor representative shall serve as an observer
(in each case, from and after the date that the Company obtains the ability to nominate any directors to the Patni board of directors) and shall have representation on committees of the Patni board of directors until Patni becomes a wholly owned
Subsidiary of the Company. 
 Section 4.9 Reporting Information. With respect to each Investor Director designated
pursuant to the provisions of this Article IV, the Majority Sponsor Investors shall cause each Investor Director to provide to the Company all necessary assistance and information related to such Investor Director that is required under
Regulation 14A under the Exchange Act to be disclosed in solicitations of proxies or otherwise, including such Person’s written consent to being named in the proxy statement (if applicable) and to serving as a director if elected. 

Section 4.10 Directors and Officers Insurance. The Company shall add each Investor Director as a beneficiary to the
Company’s (and its Subsidiary’s to the extent such Investor Director is a director of such Subsidiary) directors’ and officers’ liability insurance policy effective from the First Closing Date (or such date as such Investor
Director is appointed pursuant to this Article IV) and shall provide all other contractual or insurance director liability or indemnification coverages provided to other members of the Board or Sub Boards (on which such Investor Director
serves). 
 ARTICLE V 
 CONSENT RIGHTS 
 Section 5.1 Investor Approval. 

(a) Except as specifically permitted or contemplated by this Agreement or the Transaction Documents, so long as the Sponsor Group
beneficially owns, in the aggregate, at least 50% of the Conversion Stock issued or issuable upon conversion of the Preferred Stock as of the Second Closing Date (or the First Closing, if the Second Closing has not yet occurred) (assuming that,
notwithstanding anything to the contrary contained in Section 8(a) of the Series B Statement, each share of the Preferred Stock is convertible on the Second Closing Date or the First Closing Date, as the case may be) (whether or not such
Conversion Stock has been issued or is held through the Preferred Stock or as a combination thereof and including for these purposes the benefit to the Investor of any accrual on the Preferred Stock before the Second Closing Date but disregarding
for these purposes any accrual on any Preferred Stock after the Second Closing Date), the Company shall not, and shall take all action possible to ensure that each Subsidiary of the Company shall not, without the prior written consent of the
Majority Sponsor Investors (which consent may be withheld in their sole discretion and provided, for the avoidance of doubt, such consent must be specific consent of the Majority Sponsor Investors as shareholders, and no vote of an Investor
Director for any action of the Board shall be deemed to 

  
 20 

 
be consent of the Majority Sponsor Investors) take any of the following actions or engage in any of the following transactions: 

(i) directly or indirectly declare or make any Restricted Payment except for (A) payments with respect to the Preferred Stock
(including redemption thereof) in accordance with the Series B Statement, (B) a cash dividend payable to holders of the Company’s Common Stock to occur in the first quarter of 2011, of up to $0.07 per share of Common Stock (to a maximum of
$4.0 million), and (C) (without duplication with clause (B) in respect of fiscal year 2011 only), cash dividends payable to holders of the Company’s Common Stock of up to 25% of the net income of the Company in respect of any given
fiscal year (each of (A), (B) and (C), a “Permitted Dividend”); 
 (ii) authorize, issue, enter into any
agreement providing for the issuance (contingent or otherwise) of (A) any notes or debt securities convertible into or exchangeable for capital stock or other equity securities, issued in connection with the issuance of capital stock or other
equity securities or containing profit participation features or (B) any capital stock or other equity securities, Options, warrants or other equity-linked securities (or any other securities convertible into or exchangeable for any capital
stock or other equity securities), except for the issuance of (1) capital stock or other equity securities to the Company or a Subsidiary of the Company, (2) Preferred Stock issued pursuant to the terms of the Purchase Agreement,
(3) the Conversion Stock, (4) grants of equity to officers, employees, directors or consultants of the Company and its Subsidiaries pursuant to the Company’s written Board-approved equity incentive plans, so long as no Event of
Noncompliance under Section 11(a)(i) of the Series B Statement is existing or continuing, (5) securities issued pursuant to any rights agreements, including, without limitations, convertible securities, Options and warrants, provided that
either (i) the Company shall have complied with this Section 5.1(a)(ii), Section 3.1 and Section 3.3, if applicable, with respect to the initial sale or grant by the Company of such rights or agreements, or
(ii) such rights or agreements existed prior to the Company’s obligations under this Section 5.1(a)(ii), Section 3.1 and Section 3.3 and are scheduled on Schedule 4.4(c) of the Disclosure Schedules to
the Purchase Agreement (it being understood that any modification or amendment to any such pre-existing right or agreement subsequent to the date of this Agreement with the effect of increasing the percentage of the Company’s fully-diluted
securities underlying such rights agreement shall not be included in this clause (ii)), (6) shares of Common Stock as consideration in a merger or acquisition of the stock or assets of another Person so long as such merger or acquisition was
consented to in accordance with Section 5.1(a)(v), (7) upon the occurrence of a stock split, stock dividend or any subdivision of the Common Stock, (8) an underwritten public offering of up to 10 million shares of Common
Stock of the Company plus an additional 15% pursuant to the overallotment option prior to the Second Closing Date with proceeds used to fund a portion of the purchase price under the Patni Purchase Agreements, at a net price per share to the Company
of no less than $16.00, (9) for the six months prior to the Put Date, the Company may make any of the issuances in Section 5.1(a)(ii) (A) or (B); provided, that the proceeds of such issuance or issuances shall be held in
a segregated account, to be used solely for the benefit of the holders of the Series B Preferred Stock upon redemption of such shares by the Company in accordance with Section 6(a) of the Series B Statement and (10) after the Second
Closing only, any underwritten public offerings of Common Stock of the Company up to 10%, in aggregate, in all such underwritten public offerings after the Second Closing Date, of the number of fully diluted shares of Common Stock (assuming
conversion of all Preferred 

  
 21 

 
Stock and Convertible Securities and exercise of all Options) issued and outstanding immediately following the Second Closing Date (each of clauses (1) through (8), a “Permitted
Issuance”); 
 (iii) reclassify or recapitalize any securities of the Company or any of its Subsidiaries by any means
(including by merger) in any manner that adversely affects the rights of the holders of Series B Preferred Stock under this Agreement or the Series B Statement; 
 (iv) directly or indirectly sell, lease, exclusively license or otherwise dispose of any equity interest in any Subsidiary or consolidated assets of the Company and its Subsidiaries of more than $20
million in value in an individual transaction or $100 million in aggregate (computed on the basis of book value, determined in accordance with GAAP, or fair market value, determined by the Board in its reasonable good faith judgment);
provided, that for the six months prior to the Settlement Date, the Company may make any disposition contemplated under Section 5.1(a)(v) without limitation; provided that the proceeds of such issuance or issuances shall be
held in a segregated account, and used solely for the benefit of the holder of the Series B Preferred Stock. 
 (v) directly or
indirectly acquire or enter into, or permit any Subsidiary to acquire or enter into, any interest in any Person or business (whether by a purchase of assets, purchase of stock, merger, loan or advances to, guarantees for the benefit of, investments
in or otherwise) or any joint venture in each case involving an amount over $40 million, individually, or $80 million in the aggregate; 
 (vi)(A) enter into any material transaction involving or relating to Patni or (B) sell any Patni shares, other than (x) after the Termination Date and (y) sales of equity securities of
Patni listed on a recognized national stock exchange of India as required in order for Patni to comply with the minimum public shareholding, “public float” or other similar requirements imposed by applicable securities Laws of India or by
any applicable rules, regulations or other requirements of such stock exchanges until Patni becomes a wholly owned Subsidiary of the Company including any reorganization, recapitalization, liquidation, dissolution, merger or similar transaction
involving Patni; 
 (vii) enter into, or permit any Subsidiary to enter into, any line of business other than the lines of
business in which those entities are currently engaged (including those in which Patni and its Subsidiaries is engaged) and other activities or lines of business reasonably related thereto in each case; 

(viii) enter into, amend, modify or supplement any agreement, commitment or arrangement with any Related Party of the Company or any of
its wholly-owned Subsidiaries, except for (A) employment arrangements and benefit programs as approved by the Board, (B) any agreements or arrangements of not more than $25,000 value and (C) as otherwise expressly contemplated by the
Transaction Documents; 
 (ix) create, incur, guarantee, assume, issue or permit any Subsidiary to create, incur, guarantee,
assume or issue, any Indebtedness, other than (A) pursuant to the Closing 

  
 22 

 
Indebtedness or (B) any additional Indebtedness up to $150 million in the aggregate beyond the Closing Indebtedness; 

(x) approve the hiring or termination of the Chief Executive Office or the Chief Financial Officer of the Company; 

(xi) make any amendment to or rescind (including in each, case by merger or consolidation) any provision of the certificate of
incorporation, articles of incorporation, by-laws or similar organizational documents of the Company or any of its Subsidiaries would directly conflict with the terms and provisions of this Agreement or the Series B Statement; 

(xii) voluntarily delist from any Trading Market; 
 (xiii) except to provide for the Investor Directors appointed pursuant to Article IV or Section 7.2, increase the size of the Board beyond 12 members; 

(xiv) commence any voluntary liquidation, bankruptcy, dissolution, recapitalization, reorganization or assignment to their creditors, or
any similar transaction; or 
 (xv) agree to any of the foregoing. 

(b) If an Event of Noncompliance under Section 11(a)(i)(A) of the Series B Statement has occurred and is continuing, the Company and
the Board shall not, and shall take all actions required to ensure that each Subsidiary of the Company shall not, except as required by law, without the prior written consent of the Majority Sponsor Investors (which consent may be withheld in its
sole discretion) take any of the following actions or engage in any of the following transactions: 
 (i) any Change of
Control; 
 (ii) any issuance, disposition, acquisition or incurrence which would be permitted under
Section 5.1(a)(ii), Section 5.1(a)(iv), Section 5.1(a)(vi) or Section 5.1(a)(ix) if no Event of Default was in existence; 
 (iii) approve the annual budget of the Company and its Subsidiaries for any fiscal year or deviate therefrom by more than 10% in the aggregate; or 

(iv) approve the employment or termination by the Board of any member of senior management of the Company. 

Such additional consent rights shall terminate at any time that at least two-thirds (66-2/3%) of such original payment default has been paid to the
holders of the Series B Preferred Stock. 
 ARTICLE VI 

INFORMATION RIGHTS 
 Section 6.1 Delivery of Financial Statements. 

  
 23 

 (a) At any time that the Preferred Stock or any Conversion Stock received on conversion
thereof is outstanding and the Company does not and is not required to file periodic reports with the SEC, the Company shall deliver to each Investor: 
 (i) as soon as practicable, but in any event within one hundred and twenty (120) days after the end of each fiscal year of the Company, consolidated financial statements of the Company and its
Subsidiaries consisting of an income statement for such fiscal year, a balance sheet, and statement of stockholder’s equity as of the end of such fiscal year, and a statement of cash flows for such fiscal year, such year-end financial reports
to be in reasonable detail, prepared in accordance with GAAP, and audited and certified by a nationally recognized accounting firm selected by the Company; 
 (ii) as soon as practicable, but in any event within sixty (60) days after the end of each of the first three quarters of each fiscal year of the Company, consolidated financial statements of the
Company and its Subsidiaries consisting of an unaudited income statement for such quarter, statement of cash flows for such quarter and an unaudited balance sheet as of the end of such quarter; 

(iii) as soon as practicable, but within 30 days after the end of each fiscal month, a management information package reflecting the
monthly financial and operating performance of the Company; 
 (iv) with respect to the financial statements called for in
Section 6.1(a)(ii), an instrument executed by the Chief Financial Officer or Chief Executive Officer of the Company certifying that such financial statements were prepared in accordance with GAAP consistently applied with prior practice
for earlier periods (with the exception of footnotes that may be required by GAAP) and fairly present in all material respects the financial condition of the Company and its Subsidiaries and its results of operation for the period specified, subject
to year-end audit adjustment. 
 Section 6.2 Reasonable Information. The Company shall, with reasonable promptness,
provide to each Investor such other information and financial data concerning the Company and its Subsidiaries as such Investor may reasonably request. 
 ARTICLE VII 
 EVENTS OF DEFAULT; REMEDIES 

Section 7.1 Events of Default. It shall be considered an “Event of Default” if: 

(a) the Company defaults on its obligations under Article IV and such default continues for thirty days and has not been waived by
the Majority Sponsor Investors; 
 (b) the Company defaults on its obligations under Section 5.1 and such default
has been continuing for 60 days after written notice by the Company and has not been waived by the Majority Sponsor Investors; provided, that the Company shall be obligated to give notice to the Investors immediately upon the Company
obtaining Company’s Knowledge of any default under Section 5.1; and provided further that if the Sponsor Investors become aware of a default other 

  
 24 

 
than by notice of the Company, then the Majority Sponsor Investors shall give written notice of such default to the Company, which notice shall be deemed notice of the Company; and
provided further, that if the Company disputes any notice of default provided by the Majority Sponsor Investors, and the position of the Majority Sponsor Investors is finally determined to be correct, then the initial date of the
default will be deemed to be the date of the event causing such default (and not the date of the notice of the Majority Sponsor Investors); or 
 (c) the Company has failed, for any reason, to file the Shelf Registration Statement by the Filing Deadline or upon expiration of the Shelf Registration Statement pursuant to the Securities Act so long as
there are Registrable Securities outstanding to file a new Shelf Registration Statement in order to keep the Shelf Registration Statement effective through the Effectiveness Period. 

Section 7.2 Remedies. 
 (a) Upon the occurrence and during the continuation of an Event of Default the Company shall provide the remedies provided for in Section 11(b) of the Series B Statement. 

(b) If at the time of an Event of Default there are no shares of Preferred Stock outstanding but the Investors continue to hold shares of
Conversion Stock, then the remedies for an Event of Default hereunder shall include the remedy provided for in Section 11(b)(ii) of the Series B Certificate, and such Section shall be deemed incorporated by reference into this Agreement and
shall be applicable mutatis mutandis, even if no Preferred Stock remains outstanding. 
 (c) If any Event of Default
exists, each holder of Series B Preferred Stock or Conversion Stock shall also have any other rights which such holder is entitled to under the Series B Statement, any contract or agreement in effect at such time and any other rights which such
holder may have pursuant to applicable law. 
 ARTICLE VIII 

MISCELLANEOUS 
 Section 8.1 Expenses. All expenses of the Investors relating to this Agreement and the other Transaction Documents shall be borne by the Investors. All fees related to the Company’s
acquisition of a majority stake in Patni shall be borne by the Company, which, for the avoidance of doubt, includes all financing related fees, transaction structuring fees, anti-trust filing fees, all fees related to any foreign currency hedging
arrangements related to such acquisition, all fees related to conducting diligence on Patni (accounting, tax, legal and other), financing, and equity documentation fees and other fees related to the Company’s investment in Patni. The fees of
McKinsey & Co. and Mr. Basab Pradhan shall be borne by the Investors. The financial advisory fees of Standard Chartered Bank with respect to this Agreement and the other Transaction Documents (other than the Patni Purchase Agreements
and any documents certificates or other instruments delivered or executed in connection therewith) shall be borne by the Investors, and the Company shall bear the fees of Standard Chartered with respect to the 

  
 25 

 
acquisition of the majority stake in Patni (should the Company decide to use Standard Chartered as an advisor). 
 Section 8.2 Amendments and Waivers. This Agreement may be amended, modified or waived only by a writing signed by the Company and (i), so long as the Initial Investor or its Affiliates hold
any Preferred Stock or Conversion Stock, the Majority Sponsor Investors or (ii) thereafter, the holders of a majority of the Preferred Stock. In the event that an Interim Funding is made under the Purchase Agreement, the parties shall work
together to make any mutually agreed amendments to this Agreement and the Series B Statement required to effectuate the intent of the parties with respect to their respective rights in the case of the addition of a closing date other than the First
Closing Date and the Second Closing Date; provided, for the avoidance of doubt, it is understood by the parties that the obligation of the Company under Section 6(c) of the Series B Statement to redeem all outstanding shares of Series B
Preferred Stock shall include any shares issued as a result of an Interim Funding. 
 Section 8.3 Notices. Unless
otherwise provided, any notice required or permitted under this Agreement shall be given in writing and shall be deemed effectively given as hereinafter described (a) if given by personal delivery, then such notice shall be deemed given upon
such delivery, (b) if given by facsimile, then such notice shall be deemed given upon receipt of confirmation of complete transmittal, (c) if given by mail, then such notice shall be deemed given upon the earlier of (i) receipt of
such notice by the recipient or (ii) three Business Days after such notice is deposited in first class mail, postage prepaid, and (d) if given by an internationally recognized overnight air courier, then such notice shall be deemed given
one Business Day after delivery to such carrier. All notices shall be addressed to the party to be notified at the address as follows, or at such other address as such party may designate written notice to the other party: 

If to the Company: 
  

			
	iGATE Corporation
	6528 Kaiser Drive
	Fremont, CA 94555
	Attention:	 	Phaneesh Murthy
	Facsimile:	 	(510) 896-3010

 With a copy to:

  

			
	Latham & Watkins LLP
	355 South Grand Avenue
	Los Angeles, CA 90071
	Attention:	 	Cynthia A. Rotell
	Facsimile:	 	(213) 891-8763

 If to the Investors:

  

	
	Viscaria Limited
	c/o Aspen Secretarial Services
	Lemesou, 77

  
 26 

			
	Elia House
	P.C. 2121, Nicosia, Cyprus
	Attention:	  	Secretary of the Company
	Facsimile:	  	+ 357 2241 8801

 With a copy to (solely in its capacity as
investment manager), which shall not constitute notice to Investor: 
  

			
	Apax Partners Europe Managers Limited
	33 Jermyn Street
	London SW1Y 6DN
	United Kingdom
	Attention:	 	Salim Nathoo
	Rohan Haldea	 	
	Facsimile:	 	+44 20 7666 6441

 With a copy to (solely in its capacity
as investment advisor), which shall not constitute notice to Investor: 
  

			
	Apax Partners India Advisers Private Limited
	2nd Floor, Devchand House
	Shivsagar Estate
	Dr Annie Besant Road
	Worli
	Mumbai 400 018
	India
	Attention:	 	Shashank Singh
	Facsimile:	 	+91 22 4050 8444

  

			
	With a copy to (which shall not constitute notice to the Investors):
	
	Kirkland & Ellis LLP
	601 Lexington Avenue
	New York, NY 10022
	Attention:	  	Frederick Tanne, P.C.
		  	Susan J. Zachman
	Facsimile:	  	(212) 446-6460

 Section 8.4
Certain Tax Matters. 
 (a) On or before the First Closing, the Initial Investor shall deliver to the Company a properly
executed Internal Revenue Service Form W-8IMY, together with all required supporting documentation, certifying that each of the beneficial owners of the Initial Investor as of the First Closing is a “withholding foreign partnership” within
the meaning of Treas. Reg. Section 1.1441 5(c)(2). If the Initial Investor transfers any of the Preferred Shares (or conversion Shares) to a Person who is an Investor, such Investor shall deliver to the Company a properly executed Internal
Revenue Service Form W-8 or W-9, as applicable. Each Investor shall notify the Company of any change in circumstances with respect to such Investor or its beneficial 

  
 27 

 
owners (including if the Investor has new or different beneficial owners) of which it is aware (i) which would modify or render invalid any claimed exemption from or reduction of
withholding, (ii) which would require the Investor to provide additional certification regarding an exemption from or reduction of withholding, or (iii) if any form or certification such Person previously delivered expires or becomes
obsolete or inaccurate in any respect. The Investor shall provide the Company with updated executed originals of such forms, as and when required by Law, or any other form prescribed by applicable Laws as a basis for claiming exemption from or a
reduction in United States federal withholding tax together with such supplementary documentation as may be prescribed by applicable Laws to permit the Company to determine any withholding or deduction required to be made. 

(b) Unless otherwise required pursuant to a determination within the meaning of Section 1313(a) of the Code, the Parties shall
(i) treat the Preferred Shares as stock which participates in corporate growth to a significant extent within the meaning of Treas. Reg. Section 1.305-5(a), and not as preferred stock for purposes of Code Section 305 and the
regulations thereunder, (ii) treat any conversion of a Preferred Share into Common Stock pursuant to the terms thereof as a “recapitalization” pursuant to Section 368(a) of the Code in which no gain or loss is recognized and no
dividend income is includable, (iii) not treat the accumulation of dividends on the Preferred Shares as taxable pursuant to Section 305 of the Code, (iv) treat any payment made in redemption of the Preferred Shares under
Section 6(c) of the Series B Statement as a payment in exchange for the Preferred Shares and not as a dividend for U.S. federal income tax purposes and (v) file all Tax Returns on a basis consistent with the foregoing. In the event of any
Tax audit or other proceeding regarding any of the foregoing, the Company shall (x) promptly notify the Initial Investor and keep the Initial Investor apprised of all stages and developments concerning such audit or other proceeding and
(y) contest in good faith, taking into account the interests of the Investors, any such audit or proceeding in a manner consistent with clauses (i) through (iv) of the first sentence of this Section 8.4(b), provided,
however, the Company shall not be prevented from settling any proposed deficiency or adjustment by any taxing authority related to the positions described in clauses (i) through (vi) of the first sentence of this
Section 8.4(b), and the Company shall not be required to litigate before any court any proposed deficiency or adjustment by any taxing authority challenging any such position, except at the Initial Investor’s request and at the
expense of the Investors. 
 (c) Indian Tax Matters. 
 (i) Unless otherwise required by a final, non-appealable decision of an Indian court of competent jurisdiction, the Parties shall (i) treat the Initial Investor as a person eligible for all of the
benefits of the Cyprus-India Income Tax Treaty (including Article 14 thereof) and (ii) unless otherwise required by a change in relevant Law after the date of this Agreement (a “Change in Law”), treat any payment (whether in
the form of cash, Conversion Stock, or other consideration) made by the Company to the Initial Investor in respect of Preferred Shares or Conversion Shares (whether in redemption, conversion, as a dividend or otherwise) (any of the foregoing, a
“Payment”) as exempt from withholding Taxes under the laws of the Republic of India (“Indian Withholding Taxes”). In the event of a Change in Law, the Company shall not deduct and withhold any Indian Withholding
Taxes from any Payment without the written consent of the Initial Investor, such consent not to be unreasonably withheld, it being understood and agreed that the withholding of consent by the Initial Investor shall be reasonable if the Initial

  
 28 

 
Investor delivers to the Company an opinion from a reputable law firm or accounting firm expert in Indian Tax matters, selected by the Initial Investor and reasonably acceptable to the Company,
(and, for the avoidance of doubt, it is agreed that any of the so-called “Big Four” accounting firms shall be acceptable) to the effect that is it more likely than not that such Payment is exempt from Indian Withholding Taxes. The Parties
agree to file all Tax Returns on a basis consistent with the foregoing. 
 (ii) The Initial Investor shall, without
duplication, bear (and pay, reimburse, indemnify and hold harmless the Company for, from and against) any and all liabilities for Indian Withholding Taxes which are ultimately imposed on the Company and that are attributable to any Payment made by
the Company to the Initial Investor. 
 (iii) The Company shall notify the Initial Investor in writing within five
(5) days upon receipt by the Company or any of its Subsidiaries of notice of any pending or threatened Indian Tax audits, assessments or administrative or judicial proceedings affecting Indian Withholding Taxes that could result in any Tax
liability for which the Initial Investor may be liable to the Company hereunder (an “Indian Withholding Tax Claim”). Such notice shall contain factual information describing any asserted Tax liability and shall include copies of any
notice or other document received from any taxing authority in respect of any such asserted Tax liability. The Initial Investor (or its designee) shall, at its own expense, have the right to control the contest of any Indian Withholding Tax Claim
provided that (i) the Company may participate in the conduct of such Indian Withholding Tax Claim at its own expense, and (ii) the settlement or other resolution of such Indian Withholding Tax Claim shall be subject to the written consent
of the Company, which consent shall not be unreasonably withheld; provided, however, that no such consent shall be required where such settlement would have no adverse effect on the Company. 

(iv) Any refund of Indian Withholding Taxes withheld with respect to a Payment made to any Investor received by the Company or any of
its Subsidiaries shall be property of the Investor with respect to whom such withholding was made. The Company shall (and shall cause its Subsidiaries to) cooperate in good faith with any affected Investor to claim any such refund as soon as is
reasonably practicable. The Company shall pay to the affected Investor any such refund within fifteen (15) days after receipt thereof. 
 Section 8.5 Assignments and Transfers by Investors. The provisions of this Agreement shall be binding upon and inure to the benefit of the Investors and their respective successors and
assigns. Subject to Section 3.6, any Investor may transfer or assign, in whole or from time to time in part, to one or more Persons the Preferred Stock or any Conversion Stock issued on conversion thereof; provided that (a) such
Investor complies with all laws applicable thereto and provides written notice of assignment to the Company promptly after such assignment is effected and (b) the transferee agrees in writing to be bound by this Agreement as if it were a party
hereto and an Investor hereunder. Notwithstanding the above, the rights set forth in Section 3.1, Section 3.2, Section 3.3, Article IV and Article V shall not inure to any Investor not a member of
the Sponsor Group and the right set forth in Article VI shall not inure to any Investor that is not at least a 10% Holder. 

  
 29 

 Section 8.6 Assignments and Transfers by the Company. This Agreement may not be
assigned by the Company (whether by operation of law or otherwise) without the prior written consent of the majority of the holders of the Preferred Stock (including any Conversion Stock received on conversion thereof). 

Section 8.7 Beneficiaries of the Agreement. The terms and conditions of this Agreement shall inure to the benefit of and be
binding upon the respective permitted successors and assigns of the parties. Nothing in this Agreement, express or implied, is intended to confer upon any Person other than the parties hereto or their respective successors and assigns any rights,
remedies, obligations, or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement. Each Person who has served as an Investor Director is hereby expressly deemed a third-party beneficiary of
Section 4.10 hereto. 
 Section 8.8 Counterparts; Facsimiles and Electronic Copies. This Agreement may
be executed in one or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. This Agreement may also be executed via facsimile or other electronic copy (including copies
sent via email), which shall be deemed an original. 
 Section 8.9 Titles and Subtitles. The titles and subtitles
used in this Agreement are used for convenience only and are not to be considered in construing or interpreting this Agreement. All references to “Section” or “Sections” refer to the corresponding Section or Sections of this
Agreement. All words used in this Agreement will be construed to be of such gender or number as the circumstances require. Unless otherwise expressly provided, the word “including” does not limit the preceding words or terms. 

Section 8.10 Severability. If any provision of this Agreement or the application of any such provision to any Person or
circumstance shall be declared by any court of competent jurisdiction to be invalid, illegal, void or unenforceable in any respect, all other provisions of this Agreement, or the application of such provision to Persons or circumstances other than
those as to which it has been held invalid, illegal, void or unenforceable, shall nevertheless remain in full force and effect and will in no way be affected, impaired or invalidated thereby. Upon such determination that any provision, or the
application of any such provision, is invalid, illegal, void or unenforceable, the parties hereto shall negotiate in good faith to modify this Agreement so as to effect the original intent of the parties hereto as closely as possible to the fullest
extent permitted by law in an acceptable manner to the end that the transactions contemplated hereby are fulfilled to the greatest extent possible. 
 Section 8.11 No Strict Construction. The language used in this Agreement shall be deemed to be the language chosen by the parties hereto to express their mutual intent, and no rule of strict
construction shall be applied against any Person. 
 Section 8.12 Further Assurances. The parties hereto shall
execute and deliver all such further instruments and documents and take all such other actions as may be necessary or reasonably required to carry out the transactions contemplated hereby and to evidence the fulfillment of the agreements herein
contained. 

  
 30 

 Section 8.13 Entire Agreement. This Agreement is intended by the parties as a
final expression of their agreement and intended to be a complete and exclusive statement of the agreement and understanding of the parties hereto in respect of the subject matter contained herein. This Agreement and the other Transaction Documents
supersede all prior agreements and understandings between the parties with respect to such subject matter. 
 Section 8.14
Governing Law; Consent to Jurisdiction; Waiver of Jury Trial. This Agreement shall be governed by, and construed in accordance with, the internal laws of the State of New York without regard to the choice of law principles thereof. Each of
the parties hereto irrevocably submits to the exclusive jurisdiction of the courts of the State of New York located in New York County and the United States District Court for the Southern District of New York for the purpose of any suit, action,
proceeding or judgment relating to or arising out of this Agreement and the transactions contemplated hereby. Service of process in connection with any such suit, action or proceeding may be served on each party hereto anywhere in the world by the
same methods as are specified for the giving of notices under this Agreement. Each of the parties hereto irrevocably consents to the jurisdiction of any such court in any such suit, action or proceeding and to the laying of venue in such court. Each
party hereto irrevocably waives any objection to the laying of venue of any such suit, action or proceeding brought in such courts and irrevocably waives any claim that any such suit, action or proceeding brought in any such court has been brought
in an inconvenient forum. EACH OF THE PARTIES HERETO WAIVES ANY RIGHT TO REQUEST A TRIAL BY JURY IN ANY LITIGATION WITH RESPECT TO THIS AGREEMENT AND REPRESENTS THAT COUNSEL HAS BEEN CONSULTED SPECIFICALLY AS TO THIS WAIVER. 

[END OF PAGE] 
 [SIGNATURE PAGE FOLLOWS] 

  
 31 

 SIGNATURE PAGE TO 

INVESTOR RIGHTS AGREEMENT 
 IN WITNESS WHEREOF, the parties have executed this Agreement or caused their duly authorized officers to execute this Agreement as of the date first above written. 

 

					
	IGATE CORPORATION
		
	By:	 	 /s/ Sujit Sircar

		 	Name:	 	Sujit Sircar
		 	Title:	 	Chief Financial Officer

 SIGNATURE PAGE TO 

INVESTOR RIGHTS AGREEMENT 
 IN WITNESS WHEREOF, the parties have executed this Agreement or caused their duly authorized officers to execute this Agreement as of the date first above written. 

 

					
	VISCARIA LIMITED
		
	By:	 	 /s/ Andreas Athinodorou

		 	Name:	 	Andreas Athinodorou
		 	Title:	 	DirectorAmended and Restated Voting and Standstill Agreement

 Exhibit 10.2 
 EXECUTION COPY 
 AMENDED AND RESTATED VOTING AND STANDSTILL AGREEMENT

 THIS AMENDED AND RESTATED VOTING AND STANDSTILL AGREEMENT (this “Agreement”) is made and entered
into as of February 1, 2011 by and among iGate Corporation, a Pennsylvania corporation, for purposes of Article V only, (the “Company”), Viscaria Limited, a private company limited by shares formed under the Laws of
Cyprus (the “Investor”) and each of Mr. Sunil Wadhwani, Wadhwani Partners No. 1 LP, Wadhwani Partners No. 2 LP, Sunil and Nita Wadhwani Family Foundation, Mr. Ashok Trivedi and The Trivedi Family Qualified
Subchapter S Trust (collectively, the “Shareholders”, and each a “Shareholder”), and hereby amends and replaces in its entirety that certain Voting and Standstill Agreement, dated as of January 10, 2011, by and
among the Company, the Investor and the Shareholders. 
 WHEREAS, the Investor is party to that certain Securities Purchase
Agreement, dated as of the date hereof, by and among the Company and the Investor (the “Purchase Agreement”). Capitalized terms used herein and not otherwise defined shall have the respective meanings ascribed to such terms in
the Purchase Agreement; and 
 WHEREAS, the Investor and the Shareholders wish to agree among themselves as to the taking of
certain actions with respect to the Shareholder Approval; and 
 WHEREAS, the Investor and the Shareholders also wish to agree
among themselves as to the taking of actions with respect to the election of certain directors to the Board; and 
 WHEREAS, the
Investor and the Shareholders also wish to agree among themselves as to the taking of actions with respect to any additional approvals of the Shareholders required to fully effectuate the Investor’s rights under Section 3.1 (Right
of First Offer) and Section 3.3 (Preemptive Rights) of the Investor Rights Agreement and Section 4(b) (Participating Dividends) of the Series B Statement with Respect to Shares; and 

WHEREAS, as a condition of the willingness of the Investor to enter into the Purchase Agreement, and as an inducement and in
consideration therefor, each Shareholder has entered into this Agreement, and 
 WHEREAS, each Shareholder owns the number of
shares of common stock, par value $0.01 per share, of the Company as set forth on Schedule A hereto (the “Common Stock”), together with any other shares of capital stock of the Company acquired (whether beneficially or of
record) by any Shareholder after the date hereof and prior to the Expiration Time (as defined in Section 1.1 hereto), including any such shares acquired by means of purchase, dividend or distribution, or issued upon the exercise of any
options or warrants or the conversion of any convertible securities or otherwise, being collectively referred to herein as the “Securities”. 
 NOW, THEREFORE, in consideration of the foregoing, the mutual covenants and agreements set forth herein, and other good and valuable consideration, the receipt and sufficiency of which is hereby
acknowledged, the parties hereto agree as follows: 

 ARTICLE I 
 VOTING; GRANT AND APPOINTMENT OF PROXIES 
 Section 1.1 Voting by the
Shareholders. From and after the date hereof until the termination of this Agreement in accordance with Article VI (the “Expiration Time”), each Shareholder irrevocably and unconditionally hereby agrees that at any
meeting (whether annual or special and each adjourned or postponed meeting) of the Company’s shareholders, however called, or in connection with any written consent of the Company’s shareholders, each Shareholder will (i) appear at
such meeting or otherwise cause its Covered Securities (as defined below) to be counted as present thereat for purposes of calculating a quorum and (ii) vote or cause to be voted (including by proxy or written consent, if applicable) all of
such Shareholder’s voting securities beneficially owned or controlled by such Shareholder as of the relevant time (the “Covered Securities”), 
  

	 	(a)	in favor of the Shareholder Approval; 

  

	 	(b)	for so long as Investor and its Affiliates hold, in the aggregate, at least one third of the Conversion Stock issuable as of the Second Closing Date (or the First
Closing, if the Second Closing has not yet occurred) (whether or not such Conversion Stock has been issued or is held through Preferred Stock or as a combination thereof), in favor of the election to the Board of (i) one director (if the total
number of directors of the Company is nine or less), and two directors (if the total number of directors of the Company is ten or more), in each case, nominated by the Investor and (ii) any Series B Directors (as defined in the Series B
Statement with Respect to Shares) in accordance with Section 11(b)(ii) of the Series B Statement with Respect to Shares; 

  

	 	(c)	in favor of any additional approvals of the shareholders of the Company required under any regulation or rule of any Trading Market (as defined in the Series B
Statement with Respect to Shares) on which the Company’s stock is listed, in order to fully effectuate the Investor’s rights under Section 3.1 (Right of First Offer) and Section 3.3 (Preemptive Rights) of the Investor Rights
Agreement and Section 4(b) (Participating Dividends) of the Series B Statement with Respect to Shares; and 

  

	 	(d)	against any other action, agreement or transaction, that is intended, that could reasonably be expected, or the effect of which could reasonably be expected, to
materially impede, interfere with, delay, postpone, discourage or adversely affect the approvals and actions in Sections 1.1(a), (b) or (c) hereto. 

Section 1.2 Voting by the Investor. Subject to the occurrence of the First Closing, from and after the effectiveness of the
First Closing until the Expiration Time, the Investor irrevocably and unconditionally hereby agrees that at any meeting (whether annual or special and each adjourned or postponed meeting) of the Company’s shareholders, however called, or in
connection with any written consent of the Company’s shareholders, the Investor will (i) appear 

  
 2 

 
at such meeting or otherwise cause its Investor Securities (as defined below) to be counted as present thereat for purposes of calculating a quorum and (ii) vote or cause to be voted
(including by written consent, if applicable) all of the Investor’s voting Preferred Stock and Conversion Stock (collectively, the “Investor Securities”) beneficially owned or controlled by the Investor as of the relevant time,

  

	 	(a)	for so long as Sunil Wadhwani and his Affiliates beneficially own, in the aggregate, not less than three percent (3%) of the total outstanding Common Stock, in
favor of the election of Sunil Wadhwani (or his nominee) to the Board; 

  

	 	(b)	for so long as Ashok Trivedi and his Affiliates beneficially own, in the aggregate, not less than three percent (3%) of the total outstanding Common Stock, in
favor of the election of Ashok Trivedi (or his nominee) to the Board; and 

  

	 	(c)	against any other action, agreement or transaction, that is intended, that could reasonably be expected, or the effect of which could reasonably be expected, to
materially impede, interfere with, delay, postpone, discourage or adversely affect the election of such Shareholder (or respective nominee) to the Board. 

 Notwithstanding anything to the contrary in this Agreement or any other Transaction Document, the Investor, the Company and each of the Shareholders acknowledge and agree that this Section 1.2
shall temporarily be of no force or effect immediately upon the occurrence and continuation of an (i) Event of Noncompliance (as defined in the Series B Statement with Respect to Shares) or (ii) Event of Default (as defined in the Investor
Rights Agreement), in each case, through the time such Event of Noncompliance or Event of Default, as applicable, shall have been cured. 
 ARTICLE II 
 GRANT OF IRREVOCABLE PROXIES; APPOINTMENT OF PROXIES 

Section 2.1 Grant of Irrevocable Proxies. From and after the date hereof until the Shareholder Approval is obtained, each
Shareholder hereby irrevocably and unconditionally grants to, and appoints, the Company and any designee thereof as such Shareholder’s proxy and attorney-in-fact (with full power of substitution), for and in the name, place and stead of such
Shareholder, to vote or cause to be voted (including by proxy or written consent, if applicable) the Covered Securities in accordance with Section 1.1(a) hereto. 
 Section 2.2 Affirmation of Irrevocable Proxy. Each Shareholder hereby affirms that the irrevocable proxy set forth in this Article II is given in connection with the execution of the
Purchase Agreement, and that such irrevocable proxy is given to secure the performance of the duties of each Shareholder under this Agreement. Each Shareholder hereby further affirms that the irrevocable proxy is coupled with an interest and, except
as set forth in this Article II, is intended to be irrevocable. If for any reason a proxy granted herein is not irrevocable, then each Shareholder agrees to vote the Covered Securities in accordance with Section 2.1 above as

  
 3 

 
instructed by the Company in writing. The parties agree that the foregoing is a voting agreement. 
 Section 2.3 Restrictions on Transfers. Each Shareholder hereby agrees that from the date hereof until the Shareholder Approval is obtained, he, she or it shall not, directly or indirectly,
(a) sell, transfer, assign, tender in any tender or exchange offer, pledge, encumber, hypothecate or similarly dispose of (by merger, by testamentary disposition, by operation of Law or otherwise), either voluntarily or involuntarily, or to
enter into any Contract, option or other arrangement or understanding with respect to the sale, transfer, assignment, pledge, lien, hypothecation or similar disposition of (by merger, by testamentary disposition, by operation of Law or otherwise),
any Covered Securities, (b) deposit any Securities into a voting trust or enter into a voting agreement or arrangement or grant any proxy, consent or power of attorney with respect thereto that is inconsistent with this Agreement, or
(c) agree (whether or not in writing) to take any of the actions referred to in the foregoing clause (a) or (b); provided, that the restrictions set forth in this Section 2.3 shall not apply to any
transfers by any Shareholder to any Person in connection with estate planning so long as such Person agrees to be bound by the terms of this Agreement. 
 Section 2.4 Inconsistent Agreements. Each Shareholder hereby covenants and agrees that, except for this Agreement, each Shareholder (a) has not entered into any voting agreement or
arrangement or voting trust with respect to the Covered Securities and (b) has not granted a proxy, consent or power of attorney with respect to the Covered Securities. Each Shareholder hereby represents that any proxies heretofore given in
respect of such Shareholder’s Covered Securities, if any, are revocable, and hereby revokes such proxies. 
 ARTICLE III

 REPRESENTATIONS, WARRANTIES AND COVENANTS 
 OF EACH SHAREHOLDER 
 Section 3.1 Representations and Warranties. Each
Shareholder represents and warrants to the Investor as follows: (a) such Shareholder, if an individual, has full legal right and capacity to execute and deliver this Agreement, to perform the Shareholder’s obligations hereunder and to
consummate the transactions contemplated hereby, (b) this Agreement has been duly executed and delivered by such Shareholder and the execution, delivery and performance of this Agreement by such Shareholder and the actions contemplated hereby
have been duly authorized by all necessary action on the part of such Shareholder and no other actions or proceedings on the part of such Shareholder are necessary to authorize this Agreement or the actions contemplated hereby, (c) assuming
this Agreement constitutes the valid and binding agreement of each of the other Shareholders and the Investor, this Agreement constitutes the valid and binding agreement of such Shareholder, enforceable against such Shareholder in accordance with
its terms, (d) the execution and delivery of this Agreement by such Shareholder does not, and the consummation of the transactions contemplated hereby and the compliance with the provisions hereof will not, conflict with or violate any Law or
agreement binding upon such Shareholder or such Shareholder’s Covered Securities, nor require any authorization, consent or approval of, or filing with, any governmental entity, except for filings with the United States Securities and Exchange
Commission by such Shareholder, and (e) except for such transfer restrictions of general applicability as may be provided under the Securities Act of 1933, 

  
 4 

 
as amended, and the “blue sky” Laws of the various states of the United States, such Shareholder owns, beneficially and of record, or controls all of his, her or its Covered Securities
(and will own, beneficially and on record, or control any additional Covered Securities acquired after the date hereof) free and clear of any proxy, voting restriction, adverse claim or other lien (other than any restrictions created by this
Agreement) and has sole voting power with respect to such Covered Securities and sole power of disposition with respect to all of such Shareholder’s Covered Securities, with no restrictions on the Shareholder’s rights of voting or
disposition pertaining thereto and no person other than such Shareholder has any right to direct or approve the voting or disposition of any of the Shareholder’s Securities. 

Section 3.2 Covenants. Each Shareholder hereby: 
 (a) agrees, prior to the Expiration Time, not to take any action that would make any representation or warranty of such Shareholder contained herein untrue or incorrect or have or would reasonably be
expected to have the effect of preventing, impeding or interfering with or adversely affecting the performance by each Shareholder of its obligations under this Agreement; 
 (b) agrees that the Company may permit the Investor to publish, if required under applicable Law, such Shareholder’s identity and ownership of Common Stock and the nature of such Shareholder’s
commitments, arrangements and understandings under this Agreement in any proxy statement used in connection with soliciting the Shareholder Approval; 
 (c) shall and does authorize the Company or its counsel to, notify the Company’s transfer agent that there is a stop transfer order with respect to all of the Covered Securities (and that this
Agreement places limits on the voting and transfer of such shares); and 
 (d) agrees that, upon request of the Investor, each
Shareholder shall execute and deliver any additional documents and take such further actions as may reasonably be deemed by the Investor to be necessary or desirable to carry out the provisions of this Agreement. 

ARTICLE IV 

REPRESENTATIONS AND WARRANTIES OF THE INVESTOR 
 Section 4.1 Representations and Warranties of the Investor. The Investor hereby represents and warrants to each of the Shareholders and the Company as follows: (a) this Agreement has been
duly and validly authorized by the Investor, (b) this Agreement has been duly executed and delivered by the Investor, (c) assuming this Agreement constitutes a valid and binding agreement of each Shareholder and the Company, as applicable,
this Agreement constitutes a valid and binding agreement of the Investor, enforceable against the Investor in accordance with its terms and (d) the execution and delivery of this Agreement by the Investor does not, and the consummation of the
transactions contemplated hereby and the compliance with the provisions hereof will not, conflict with or violate any Law or agreement or organizational documents binding upon the Investor, nor require any authorization, consent or

  
 5 

 
approval of, or filing with, any governmental entity except for filings with the United States Securities and Exchange Commission by such Shareholder. 

ARTICLE V 

REPRESENTATIONS, WARRANTIES AND COVENANTS OF THE COMPANY 
 Section 5.1 Representations and Warranties of the Company. The Company hereby represents and warrants to each of the Shareholders and to the Investor as follows: (a) this Agreement has
been duly and validly authorized by the Company, (b) this Agreement has been duly executed and delivered by the Company, (c) assuming this Agreement constitutes a valid and binding agreement of each Shareholder and the Investor, as
applicable, this Agreement constitutes a valid and binding agreement of the Company, as applicable, enforceable against the Company, as applicable, in accordance with its terms and (d) the execution and delivery of this Agreement by the Company
does not, and the consummation of the transactions contemplated hereby and the compliance with the provisions hereof will not, conflict with or violate any Law or agreement or organizational documents binding upon the Company, nor require any
authorization, consent or approval of, or filing with, any governmental entity except for filings with the United States Securities and Exchange Commission by the Company. 
 Section 5.2 Covenants. The Company hereby agrees to vote or cause to be voted the Covered Securities only in accordance with this Agreement. 

ARTICLE VI 

TERMINATION 

Section 6.1 This Agreement shall automatically terminate and be of no further force or effect upon the date on which both the
Shareholder Approval has been obtained and the Shareholders are no longer required to vote to elect each Series B Director pursuant to Section 1.1(b) of this Agreement; provided that this Agreement shall automatically terminate
upon the termination of the Purchase Agreement in accordance with its terms prior to the First Closing. Notwithstanding the preceding sentence, Article VII shall survive any termination of this Agreement. Nothing in this Article VI
shall relieve or otherwise limit any party of liability for willful breach of this Agreement. 
 ARTICLE VII 

MISCELLANEOUS 

Section 7.1 Expenses. Except as otherwise may be agreed in writing, all costs, fees and expenses incurred in connection with
this Agreement and the transactions contemplated hereby shall be paid by the party incurring or required to incur such costs, fees and expenses. 
 Section 7.2 Notices. Unless otherwise provided, any notice required or permitted under this Agreement shall be given in writing and shall be deemed effectively given as hereinafter described
(a) if given by personal delivery, then such notice shall be deemed given upon such delivery, (b) if given by facsimile or electronic transmission, then such notice shall be deemed given upon receipt of confirmation of complete
transmittal, (c) if given by mail, then such notice shall be deemed given upon the earlier of (i) receipt of such notice by the recipient or (ii) three days after such notice is deposited in first class mail, postage prepaid, and
(d) if given 

  
 6 

 
by an internationally recognized overnight air courier, then such notice shall be deemed given one Business Day after delivery to such carrier. All notices shall be addressed to the party to be
notified at the address as follows, or at such other address as such party may designate by written notice to the other party: 

To the Company: 
 iGate Corporation 
 6528 Kaiser Drive, 

Fremont, CA 94555 
 Attention: Phaneesh Murthy 
 Fax: (510) 896-3010 

with a copy to (which shall not constitute notice): 
 Latham & Watkins LLP 
 355 South Grand Avenue 

Los Angeles, CA 90071-1560 
 Attention: Cynthia A. Rotell 
 Fax: (213) 891-8763 

To the Investor: 
 Viscaria Limited 
 c/o Aspen Secretarial Services 

Lemesou, 77 

Elia House 

P.C. 2121, Nicosia, Cyprus 
 Attention: Secretary of the Company 
 Fax: + 357 2241 8801 

with copies to (solely in its capacity as investment advisor or investment manager as the case may be), which shall not constitute notice
to Investor: 
 Apax Partners Europe Managers Limited 
 33 Jermyn Street 
 London SW1Y 6DN 

United Kingdom 

Attention: Salim Nathoo 
 Fax: +44 20 7666 6441 
 and 

  
 7 

 Apax Partners India Advisers Private Limited 

2nd Floor, Devchand House 
 Shivsagar Estate 
 Dr Annie Besant Road 

Worli, Mumbai 400 018, India 
 Attention:  Shashank Singh 

                  Rohan Haldea 

Fax: +91 22 4050 8444 
 with a copy to (which shall not constitute notice to Investor): 

Kirkland & Ellis LLP 
 601 Lexington Avenue 
 New York, New York 10022 

Attention:  Frederick Tanne 
                   Susan J. Zachman 
 Fax: 212-446-6460 
 To the Shareholders: 

1000 Commerce Drive, 
 Suite 500 
 Pittsburgh, PA 15275 

Attention: Sunil Wadhwani 
 Fax: 412-291-1188 
 and 

1000 Commerce Drive, 
 Suite 500 
 Pittsburgh, PA 15275 

Attention: Ashok Trivedi 
 Fax: 412-291-1154 
 with a copy to (which shall not constitute notice):

 Reed Smith LLP 
 225 Fifth Avenue 
 Pittsburgh, PA 15222-2716 

Attention: James J. Barnes 
 Fax: (412) 288-3063 
 Section 7.3 Amendments; Waivers. At any
time prior to the Expiration Time, any provision of this Agreement may be amended or waived if, and only if, such amendment or waiver is in writing and signed, in the case of an amendment, by the Company, each of the Shareholders and the Investor,
or in the case of a waiver, by the party against whom the waiver is to be effective. Notwithstanding the foregoing, no failure or delay by the Company, the 

  
 8 

 
Shareholders or the Investor in exercising any right hereunder shall operate as a waiver thereof nor shall any single or partial exercise thereof preclude any other or further exercise of any
other right hereunder. 
 Section 7.4 Assignment; Binding Effect. Neither this Agreement nor any of the rights,
interests or obligations hereunder shall be assigned by any of the parties hereto (whether by operation of Law or otherwise) without the prior written consent of the other parties, except that each Investor may assign, in its sole discretion, any of
or all of its rights, interest and obligations under this Agreement to any Affiliate of an Investor, but no such assignment shall relieve such Investor of its obligations hereunder. Subject to the preceding sentence, this Agreement shall be binding
upon and shall inure to the benefit of the parties hereto and their respective permitted successors and assigns. Each Investor shall cause any assignee thereof to perform its obligations under this Agreement and shall be responsible for any failure
of such assignee to comply with any representation, warranty, covenant or other provision of this Agreement. 
 Section 7.5
No Partnership, Agency, or Joint Venture. This Agreement is intended to create, and creates, a contractual relationship and is not intended to create, and does not create, any agency, partnership, joint venture or any like relationship
between the parties hereto. 
 Section 7.6 Entire Agreement; Benefit. This Agreement is intended by the parties as a
final expression of their agreement and intended to be a complete and exclusive statement of the agreement and understanding of the parties hereto in respect of the subject matter contained herein. This Agreement and the other Transaction Documents
supersede all prior agreements and understandings between the parties with respect to such subject matter. 
 Section 7.7
Severability. If any provision of this Agreement or the application of any such provision to any Person or circumstance shall be declared by any court of competent jurisdiction to be invalid, illegal, void or unenforceable in any respect, all
other provisions of this Agreement, or the application of such provision to Persons or circumstances other than those as to which it has been held invalid, illegal, void or unenforceable, shall nevertheless remain in full force and effect and will
in no way be affected, impaired or invalidated thereby. Upon such determination that any provision, or the application of any such provision, is invalid, illegal, void or unenforceable, the parties hereto shall negotiate in good faith to modify this
Agreement so as to effect the original intent of the parties hereto as closely as possible to the fullest extent permitted by Law in an acceptable manner to the end that the transactions contemplated hereby are fulfilled to the greatest extent
possible. 
 Section 7.8 Governing Law. This Agreement, and all claims or causes of action (whether at Law, in
contract or in tort) that may be based upon, arise out of or relate to this Agreement, or the negotiation, execution or performance hereof, shall be governed by and construed in accordance with the Laws of the State of Pennsylvania, without giving
effect to any choice or conflict of law provision or rule (whether of the State of Pennsylvania or any other jurisdiction) that would cause the application of the Laws of any jurisdiction other than the State of Pennsylvania. 

Section 7.9 Jurisdiction; Enforcement. Each of the parties hereto irrevocably submits to the exclusive jurisdiction of the
courts of the State of New York located in New York County 

  
 9 

 
and the United States District Court for the Southern District of New York for the purpose of any suit, action, proceeding or judgment relating to or arising out of this Agreement and the
transactions contemplated hereby. Service of process in connection with any such suit, action or proceeding may be served on each party hereto anywhere in the world by the same methods as are specified for the giving of notices under this Agreement.
Each of the parties hereto irrevocably consents to the jurisdiction of any such court in any such suit, action or proceeding and to the laying of venue in such court. Each party hereto irrevocably waives any objection to the laying of venue of any
such suit, action or proceeding brought in such courts and irrevocably waives any claim that any such suit, action or proceeding brought in any such court has been brought in an inconvenient forum. EACH OF THE PARTIES HERETO WAIVES ANY RIGHT TO
REQUEST A TRIAL BY JURY IN ANY LITIGATION WITH RESPECT TO THIS AGREEMENT AND REPRESENTS THAT COUNSEL HAS BEEN CONSULTED SPECIFICALLY AS TO THIS WAIVER. 
 Section 7.10 Remedies. The Company and each of the Shareholders acknowledges that monetary damages would not be an adequate remedy in the event that any covenant or agreement in this Agreement
is not performed in accordance with its terms, and it is therefore agreed that, in addition to and without limiting any other remedy or right it may have, the Investor will have the right to an injunction, temporary restraining order or other
equitable relief in any court of competent jurisdiction enjoining any such breach and enforcing specifically the terms and provisions hereof. The Company and each of the Shareholders agrees not to oppose the granting of such relief in the event a
court determines that such a breach has occurred, and to waive any requirement for the securing or posting of any bond in connection with such remedy. All rights, powers, and remedies provided under this Agreement or otherwise available in respect
hereof at Law or in equity shall be cumulative and not alternative, and the exercise or beginning of the exercise of any thereof by the Investor shall not preclude the simultaneous or later exercise of any other such right, power or remedy by such
party. 
 Section 7.11 Titles and Subtitles; Rules of Construction. The titles and subtitles used in this Agreement
are used for convenience only and are not to be considered in construing or interpreting this Agreement. All references to “Section” or “Sections” refer to the corresponding Section or Sections of this Agreement. Defined terms
used in this Agreement in the singular shall include the plural and vice versa. Whenever the words “include,” “includes” or “including” are used in this Agreement, they are deemed to be followed by the words
“without limitation.” Any definitions used herein defined in the plural shall be deemed to include the singular as the context may require and any definitions used herein defined in the singular shall be deemed to include the plural as the
context may require. Wherever reference is made herein to the male, female or neuter genders, such reference shall be deemed to include any of the other genders as the context may require. 

Section 7.12 No Strict Construction. The language used in this Agreement shall be deemed to be the language chosen by the
parties hereto to express their mutual intent, and no rule of strict construction shall be applied against any Person. 

Section 7.13 Counterparts; Facsimiles and Electronic Copies. This Agreement may be executed in two or more counterparts, each
of which shall be deemed an original, but all of which together shall constitute one and the same instrument. This Agreement may also be 

  
 10 

 
executed via facsimile or other electronic copy (including copies sent via email), which shall be deemed an original. 
 [Signature Pages to Follow] 

  
 11 

 IN WITNESS WHEREOF, the parties hereto have duly executed and delivered this Agreement as of
the date and year first written above. 
  

									
		 		 	COMPANY:
			
	FOR PURPOSES OF ARTICLE V ONLY:	 		 	iGATE CORPORATION
				
		 		 	By:	 	 /s/ Sujit Sircar

		 		 		 	Name:	 	Sujit Sircar
		 		 		 	Title:	 	Chief Financial Officer

 [Signature Page to
Amended and Restated Voting and Standstill Agreement] 

 IN WITNESS WHEREOF, the parties hereto have duly executed and delivered this Agreement as of
the date and year first written above. 
  

					
	VISCARIA LIMITED
		
	By:	 	 /s/ Andreas Athinodorou

		 	Name:	 	Andreas Athinodorou
		 	Title:	 	Director

 [Signature Page to Amended
and Restated Voting and Standstill Agreement] 

 IN WITNESS WHEREOF, the parties hereto have duly executed and delivered this Agreement as of
the date and year first written above. 
  

	
	SHAREHOLDER:
	
	 /s/ Sunil Wadhwani

	SUNIL WADHWANI

 [Signature Page
to Amended and Restated Voting and Standstill Agreement] 

 IN WITNESS WHEREOF, the parties hereto have duly executed and delivered this Agreement as of
the date and year first written above. 
  

					
	SHAREHOLDER:
	
	WADHWANI PARTNERS NO. 1 LP
		
	By:	 	 /s/ Sunil Wadhwani

		 	Name:	 	Sunil Wadhwani
		 	Title:	 	Majority in Interest of the General Partners

 [Signature Page to Amended and Restated Voting and Standstill Agreement] 

 IN WITNESS WHEREOF, the parties hereto have duly executed and delivered this Agreement as of
the date and year first written above. 
  

					
	SHAREHOLDER:
	
	WADHWANI PARTNERS NO. 2 LP
		
	By:	 	 /s/ Sunil Wadhwani

		 	Name:	 	Sunil Wadhwani
		 	Title:	 	Majority in Interest of the General Partners

 [Signature Page to Amended and Restated Voting and Standstill Agreement] 

 IN WITNESS WHEREOF, the parties hereto have duly executed and delivered this Agreement as of
the date and year first written above. 
  

					
	SHAREHOLDER:
	
	SUNIL AND NITA WADHWANI FAMILY FOUNDATION
		
	By:	 	 /s/ Sunil Wadhwani

		 	Name:	 	Sunil Wadhwani
		 	Title:	 	Director, President and Treasurer

[Signature Page to Amended and Restated Voting and Standstill Agreement] 

 IN WITNESS WHEREOF, the parties hereto have duly executed and delivered this Agreement as of
the date and year first written above. 
  

	
	SHAREHOLDER:
	
	 /a/ Ashok K. Trivedi

	ASHOK K. TRIVEDI

 [Signature Page
to Amended and Restated Voting and Standstill Agreement] 

 IN WITNESS WHEREOF, the parties hereto have duly executed and delivered this Agreement as of
the date and year first written above. 
  

					
	SHAREHOLDER:
	
	THE TRIVEDI FAMILY QUALIFIED SUBCHAPTER S TRUST
		
	By:	 	 /s/ Ashok K. Trivedi

		 	Name:	 	Ashok K. Trivedi
		 	Title:	 	Co-Trustee

 [Signature Page to
Amended and Restated Voting and Standstill Agreement] 

 Schedule A 

 

					
	 Shareholder
	  	Shares of Common Stock	 
		
	 Sunil Wadhwani
	  	 	10,106,551	  
		
	 Wadhwani Partners No. 1 LP
	  	 	60,124	  
		
	 Wadhwani Partners No. 2 LP
	  	 	1,820,000	  
		
	 Sunil and Nita Wadhwani Family Foundation
	  	 	515,000	  
		
	 Ashok K. Trivedi
	  	 	10,714,082	  
		
	 The Trivedi Family Qualified Subchapter S Trust
	  	 	1,787,593

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00183-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00183-of-00352.parquet"}]]